CN1314445C - Pulmonary administration of chemically modified insulin - Google Patents

Abstract

The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.

Description

The pulmonary administration of chemically modified insulin

Invention field

The present invention relates to by suction be sent to pulmonary biologically active, hydrophilic polymer-modified derivatives of insulin.The preparation and the medication of these derivants also are provided simultaneously.

Background of invention

A kind of polypeptide hormone that insulin produces in the pancreas beta cell of normal (not suffering from diabetes) study subject.Insulin human is 51 amino acid whose polypeptide hormones, and molecular weight is about 5800 dalton.Insulin molecule is formed (an A chain and a B chain) by two peptide chains, contain in the subunit and two subunits between disulfide bond.The A chain is made up of 21 aminoacid, and the B chain is made up of 30 aminoacid.Two chain formation of insulin a kind of structure of high-sequential, several alpha-helixs district is all arranged in A chain and B chain.What is interesting is, isolated insulin chain be do not have active.In solution, insulin can exist with the form of monomer, dimer or six aggressiveness.At the high concentrate formulation insulin that is used for subcutaneous treatment is six aggressiveness, but has just become monomeric form after it is diluted in body fluid.Insulin is essential for adjusting carbohydrate metabolism, blood sugar lowering level; The general defective of insulin causes diabetes.The existence of diabetic depends on continually, administration of insulin chronically, to keep the acceptable blood sugar level.

Existing insulin preparation has defective, can cause serious medical complication when the treatment diabetes.For example, the diabetes patient the insulin zinc preparation of the standard of frequent use be the microcrystal suspension of six aggressiveness insulins of non-activity.Microcrystal insoluble and subsequently six aggressiveness be dissociated into activated monomeric form, can cause delay and study subject difference (F.Liu etc., Bioconjugate Chem., 8, the 664-672 (1997) of absorption of insulin in the blood flow; T.Uchio etc., Adv.Drug Del.Rev., 35,289-306 (1999); K.Hinds etc., BioconjugateChem., 11,195-201 (2000)).The preparation of insulin also is subjected to the puzzlement of physical instability, because insulin is tending towards forming microfilament and infusible precipitate.For the preparation of planning to use in insulin pump, precipitation is the problem of particular importance.The insulin of preparation also tends to chemical degradation, the deamination of non-enzymatic for example, and form high-molecular weight converted product such as covalently bound insulin dimer (Brange.J. etc., Pharm.Res., 9,715-726 (1992); Brange J. etc., Pharm.Res., 9,727-734 (1992)).Existing important evidence shows, may be because the existing of the covalent polymer of these insulins (Robbins, D.C. etc., Diabetes, 36,838-841 (1987)) to the generation of the immunne response of insulin.In addition, even highly purified insulin human also has slight immunogenicity (Kim, the same).

Except preparation instability problem above-mentioned, from the viewpoint of administration, existing insulin treatment also has many shortcomings.The most frequently used insulin administration mode is a subcutaneous injection, normally at abdominal part or thigh.Insulin also can pass through intravenous or the administration of intramuscular mode.Inject insulin once or twice in order blood glucose to be maintained the acceptable level, to need every day usually, also will replenish insulin injection when needed in addition.The active treatment of diabetes may need more frequent injection, and at this moment patient uses the one family diagnostic kit to monitor blood sugar level closely.For multiple consideration, be unwelcome with injection system administration insulin.At first, many patients find, are quite difficult and loaded down with trivial details to oneself injecting continually according to the needs of keeping acceptable blood sugar level.In fact, many II type patients have an acupuncture treatment for fear and are reluctant to use continuously all the year round insulin.Thisly unwillingly may cause uncomplaisance, may threat to life under serious situation.In addition, the whole body of hypodermic insulin absorbs quite slow, even under the situation of using fast effect insulin preparation, also need 45 to 90 minutes usually.Therefore, thereby providing a kind of alternate insulin preparation and route of administration not to need self-injection, and can make insulin fast, play effectiveness to general, is a target for a long time.

Explored the preparation of many non-injections, as oral or snuffing preparation, still, the result of these effort does not cause developing commercial available insulin delivery system (Patton etc. based on oral or snuffing as yet, Adv.Drug Delivery Reviews, 1,35 (2-3), 235-247 (1999)), this mainly is because bioavaliability very low and variable (Hilsted, J. etc., Diabetologia, 38,680-684 (1995)).Although using with absorption enhancer to increase bioavaliability, these medicaments can damage mucosa.

But the insulin preparation that can suck is developed, shows quite outstandingly aspect many problems above-mentioned overcoming.For example, U.S. Patent No. 5,997,848 (Patton etc., InhaleTherapeutic Systems, Inc. (Inhale Therapeutics Systems, Inc)) described the dry powder formulations of insulin, its (1) at room temperature is that chemistry and physics are stable, and (2) when sucking, can pass through the epithelial cell fast Absorption of alveolar region in blood circulation.Wherein this fast effect insulin preparation and the method for Miao Shuing do not need loaded down with trivial details self-injection, and schedule to last demonstration in trimestral human efficiency's research at one, in I type and II type insulin dependent diabetes mellitus (IDDM) people, compare the glucose control ability (Patton etc. that provide equal with subcutaneous injection, Adv.DrugDelivery Reviews, 1,35 (2-3), 235-247 (1999)).The dry powder insulin preparation that Patton etc. describe in the problem that has overcome preparation instability and patient's uncomplaisance, in order to control glucose level effectively, still needs continually (for example when having dinner) to suck insulin.In addition, thisly can suck the preparation of insulin type based on fast effect, for I type and part type ii diabetes people, its typical insulin application method still need be injected protamine zine insulin one time at h.d..Therefore, still need a kind of activated, soluble, stable insulin type, it does not need medication continually, promptly is Insulin Glargin, preferably by the suction administration.

The feature of ideal Insulin Glargin is that onset is very slow, but effectiveness is lasting, peak value is mild relatively.Existing long-acting injectable insulin preparation, for example ultralente (the insulin zinc suspension of super snail) and protamine zinc insulin suspension are very not satisfied.These preparations are tending towards the peak occurring and the insulin concentration on low basis can not be provided, and unpredictable, and the persistent period of general action is no more than about one day.The ultralente insulin has the long half-life, make and be difficult to determine its suitableeest dosage range, and protamine zinc insulin is because its unpredictability and render a service overlong time and seldom use (Goodman and Gilman, " The Pharmacological Basis of Therapeutics (therapeutic pharmacological basis) ", the 9th edition, Hardman and Limbird edit, 1996, the 1500 pages).Other unsuccessful long-acting injectable insulin preparation of having explored comprises the insulin and the insulin hexamer aggressiveness cobalt preparation (Hoffman, A., Ziv, E., Clin.Pharmacokinet, 33 (4): 285-301, (1997)) of albumin bound.

Many long-acting pulmonarys also are explored with insulin preparation.Comprising containing with respect to the insulin liposome (Liu.F-Y etc. of excessive amount of lipid greatly, Pharm.Res.10,228-232, (1983)), porous poly lactic coglycolic acid (PLGA) insulin granule (Edwards, D.A. etc., Science 276 (5320), 1868-1871 (1997)), PLGA nanosphere (Kawashima, the Y. etc. of atomizing, J.Controlled Release, 62 (1-2): 279-287 (1999)) and phospholipid/PI preparation (Vanbever, R. etc., Proc.Control Rel.Bioact.Mater., 25,261-262 (1998)).Unfortunately, it is not satisfied that all these preparations all have been proved to be, or owing to bioavaliability when being applied to rat is low, or because preparation deficiency.Therefore, still have demand for a long time to the suitableeest Insulin Glargin, they should be biologically active, physics and chemically stable, water miscible and be preferably monomer.In the ideal case, such preparation preferably is suitable for pulmonary administration.

Summary of the invention

From on the one hand, the present invention is based upon on the basis of analgesic composition, and this analgesic composition can be used for by deep lung to the systemic blood administration that circulates.Specifically, compositions of the present invention has comprised a kind of conjugate, is covalently bound on the hydrophilic polymer molecule that one or more non-naturals exist and is formed by insulin.In a preferred embodiment, the hydrophilic polymer that is covalently bonded in the non-natural existence on the insulin is a kind of poly alkylene glycol, Polyethylene Glycol (PEG) for example is although also can be used for the hydrophilic polymer that other non-natural exists comparably in all embodiments of this proposition.

In general, insulin-polymer conjugates of the present invention is compared with natural insulin with showing improved pharmacokinetics and drug effect character, particularly when pulmonary administration.In one embodiment, by pulmonary and deep lung administration the time, show good absolute bioavaliability at this PEG-insulin bonder that provides.In a specific embodiment, PEG-insulin bonder of the present invention is characterised in that it has the absolute pulmonary bioavaliability that is higher than natural insulin.In the preferred case, PEG-insulin bonder of the present invention is characterised in that it has and is higher than natural insulin 1.5-2.0 absolute pulmonary bioavaliability doubly at least.In more preferred, it is about 15% that PEG-insulin bonder of the present invention is characterised in that its absolute pulmonary bioavaliability exceeds, and more preferably exceeds approximately 20% under the situation, perhaps exceeds about 30% under most preferred case.

In another embodiment, PEG-insulin bonder of the present invention is when by pulmonary administration, its Tmax value (reaching the required time of Cmax) shows at least 1.5 times to natural insulin, or under more preferably situation at least 2 or 3 times to natural insulin, or more preferably under the situation at least 5 times to natural insulin.

The PEG that uses in the conjugate of the present invention can have several different characteristics.In one embodiment of the invention, the polyalkylene glycol moiety of PEG-insulin bonder described here end group inert by endways or anergy seals, for example alkoxyl or more particularly a methoxyl group.

In another embodiment, the polyalkylene glycol moiety of conjugate will have a structure that is particularly suitable for being connected on the insulin, comprise the linear Polyethylene Glycol and the Polyethylene Glycol of racemosusization or side chain.In another embodiment, a PEG-insulin bonder can contain two deutero-insulin molecules of simple function, couples together (insulin-PEG-insulin) by two activated polyglycol between them.In addition, an insulin molecule in this " dumbbell " structure can also be modified by other PEG.

In another embodiment, a PEG-insulin bonder of the present invention contains the Polyethylene Glycol of a bifurcated, end at polymer chain has a component, also has two free reactive groups (or organizing two groups) that are connected on the component to be used for the covalent bond insulin more.In this embodiment of the present invention, the branched structure of Polyethylene Glycol makes polymer chain can connect two or more insulin molecules.

The polyalkylene glycol moiety of insulin bonder of the present invention can be chosen wantonly and contain one or more degradable connections.

In general, insulin is covalently bound on the PEG by a coupling part that is positioned at the PEG end.The preferred coupling part of Shi Yonging comprises that those are suitable for and have the bonded part of amino group of reactive insulin, for example N-hydroxy-succinamide active ester, activated carbon hydrochlorate, aldehyde and an acetal in the present invention.

In another embodiment, be covalently bonded in the conjugate of the present invention PEG on the insulin will contain from about two to about 300 (OCH ₂CH ₂) subunit, in the preferred case from about 4 to 200 subunits, under more preferably situation from about 10 to 100 subunits.

In another embodiment, be covalently bonded in PEG on the insulin will have nominal mean molecule quantity from about 200 to about 10,000 dalton.In a preferred embodiment, PEG will have nominal mean molecule quantity from about 200 to about 5000 dalton.In an embodiment that is more preferably, PEG will have nominal mean molecule quantity from about 200 to about 2000 dalton or from about 200 to about 1000 dalton.

In a specific embodiment, the insulin of conjugate partly contains natural insulin human.

In another embodiment, the purity that the conjugate in the present composition has is greater than about 90% (promptly in the conjugate part of compositions, have 90% weight or abovely be one or more PEG-insulins).That is to say that compositions of the present invention is characterized by and contains highly purified bonded insulin composition, promptly do not exist in the compositions can detection limit free Polyethylene Glycol species and other impurity relevant with PEG.

In one embodiment, a kind of compositions of the present invention contains a kind of conjugate, wherein insulin on its one or more amino sites with the PEG covalent bond.The insulin that comprises in a kind of compositions of the present invention can be mono-substituted (promptly having only a PEG to be covalently bound on it).According to the present invention, specific single PEG-insulin bonder that replaces contains a polyalkylene glycol moiety that is covalently bound on the insulin molecule, and binding site is selected from PheB1, GlyA1 and LysB29.

In a preferred embodiment, peg moiety covalently bind on the PheB1 site of insulin.In one embodiment, about at least 75% B-1Phe site and PEG covalent bond on the insulin.In another embodiment, about at least 90% B-1Phe site and PEG covalent bond on the insulin.

Compositions of the present invention also can contain a kind of mixture, and it is closed with the PEG-insulin of double combination by the unijunction with above-mentioned one or more features and forms.Such compositions can also contain three bonded PEG-insulins.

In another embodiment, a kind of PEG-insulin bonder of the present invention is characterised in that it with respect to non-PEGization or natural insulin, and Proteolytic enzyme speed reduces.

A kind of compositions of the present invention can also contain the mixture of PEG-insulin bonder and that non-chemically modify or natural insulin.

In addition, above-mentioned compositions is an atomised form.

Compositions of the present invention can be dissolved or suspended in the liquid, or is dried forms, also can contain pharmaceutically useful excipient in addition.

In addition, also provide a kind of bioactive polyethylene glycol-insulin conjugate at this, it is adapted to pass through inhalation to deep lung.

On the other hand, the invention provides a kind of method that the PEG-insulin bonder is sent in the mammalian subject that needs it, administration by the PEG-analgesic composition that sucks aforesaid atomised form.

On the other hand, the present invention also provides a kind of method, is used to provide a kind of analgesic composition that passes through the non-immunogenic basically of pulmonary administration.This method comprises the following steps: on the said molecule that insulin is covalently bound to the hydrophilic polymeric combination that one or more non-naturals exist, by sucking the pulmonary that compositions is administered into study subject, insulin enters into blood circulation by pulmonary as a result then.

A kind of method also is provided on the other hand, has been used to provide a kind of long lasting analgesic composition that is administered into human subject pulmonary.This method comprises: provide a kind of compositions that contains insulin-hydrophilic polymeric combination thereby insulin is covalently bound on the hydrophilic polymer that one or more non-naturals exist, then by sucking the pulmonary that said composition is administered into study subject.In dosing step, insulin enters blood circulation by pulmonary, and the insulin level that raises in the blood after administration can be kept 8 hours at least.

PEG-insulin bonder of the present invention when atomizing and by behind the inhalation, can be used for treating diabetes (DM).

After having read following detailed, these and other purpose and characteristics of the present invention will become more very clear.

The accompanying drawing summary

Fig. 1 is the PEG-insulin bonder (" 750-2 peg insulin ") of an example and the enzymolysis rate diagram of the insulin contrast of a unmodified, describes in detail in embodiment 6;

After Fig. 2 is the analgesic composition of (5K peg insulin) and non-PEGization of PEGization of intravenous administration example, the average insulin concentration map in the serum (detailed description in embodiment 7);

Fig. 3 be the exemplary PEGization of intravenous administration (5K peg insulin) with the analgesic composition of non-PEGization after blood sugar concentration figure (detailed description in embodiment 7);

Fig. 4 behind the insulin human (every animal 40 μ g) of male rat intratracheal instillation PEGization (every animal 150 μ g 5K peg insulins) and non-PEGization, the average insulin concentration map in the serum (embodiment 8);

The average blood glucose concentration figure (embodiment 8) of Fig. 5 behind the insulin human (every animal 40 μ g) of male rat intratracheal instillation PEGization (every animal 150 μ g 5K peg insulins) and non-PEGization;

Fig. 6 behind the insulin human of male rat intratracheal instillation PEGization (750-1 peg insulin) and non-PEGization, the average insulin concentration map in the serum (embodiment 9);

The average blood sugar concentration map (embodiment 9) of Fig. 7 behind the insulin human of male rat intratracheal instillation PEGization (750-1 peg insulin) and non-PEGization;

Fig. 8 behind the insulin human (every animal 80 μ g) of male rat intratracheal instillation PEGization (750-1 peg insulin, every animal 80 and 160 μ g) and non-PEGization, the average insulin concentration map in the serum (embodiment 10);

The average blood sugar concentration map (embodiment 10) of Fig. 9 behind the insulin human (every animal 80 μ g) of male rat intratracheal instillation PEGization (750-1 peg insulin, every animal 80 and 160 μ g) and non-PEGization;

Figure 10 behind the insulin human (every animal 80 μ g) of male rat intratracheal instillation PEGization (750-2 peg insulin, every animal 80 μ g) and non-PEGization, the average insulin concentration map in the serum (embodiment 11);

The average blood sugar concentration map (embodiment 11) of Figure 11 behind the insulin human (every animal 80 μ g) of male rat intratracheal instillation PEGization (750-1 peg insulin, every animal 80 μ g) and non-PEGization;

The average blood sugar concentration map (embodiment 12) of Figure 12 behind the insulin human (every animal 80 μ g) of male rat intratracheal instillation PEGization (2K peg insulin, every animal 300 μ g, 600 μ g, 900 μ g and 1200 μ g) and non-PEGization;

After Figure 13 is the analgesic composition of exemplary PEGization of intravenous administration (2K peg insulin) and non-PEGization, the average insulin concentration map in the serum (in embodiment 13, describing in detail); And

Figure 14 be the exemplary PEGization of intravenous administration (2K peg insulin) with the analgesic composition of non-PEGization after average blood sugar concentration map (detailed description in embodiment 13).

Detailed Description Of The Invention

For by pulmonary administration to lung, the design of various representational PEG-insulin bonders, synthetic and characterize by optimization. Although the former existing description of the preparation of PEG-insulin molecule utilizes the covalent bond with PEG that the long-acting insulin preparation that sucks is provided, formerly not yet be proved. Therefore, the challenge that the applicant faces, provide the PEG-insulin bonder, the PEG chain that wherein covalently bind on the insulin molecule has the suitableeest balanced number, position, structure and molecular weight, be suitable for being administered in the systemic circulation system thereby provide, preferably pass through the analgesic composition of deep lung administration. Can see from the description of front, it is shocking, the inventor has found that the insulin preparation that some PEG-modifies has following one or more characteristics: they are bioactive for (1), namely show about at least 5% natural insulin activity, or its biologically active is compared at least with natural insulin or is substantially kept or only slightly reduces in the preferred case, perhaps in more preferably situation, its specific activity natural insulin is high; (2) they enter blood flow (opposite in lung with " adhesion ") from pulmonary absorption; (3) they are that chemistry and physics are stable; (4) they are when the pulmonary administration, can be after administration the insulin level in the blood be elevated to more than a reference value about at least 8 hours; (5) they are attacked the enzymolysis of insulin-degrading enzyme and have resistance; And (6) by inhalation the time, the long half time that they show is in the insulin of non-PEGization. The details of these characteristics will become obvious after the description below having read.

I, definition

Has the meaning of appointment in this used following term.

Unless clearly explanation is arranged in context, and in claims of specification and appendix, singulative has included plural concept.

Comprise proinsulin in this used " insulin " its meaning, and comprised any the have part or all of primary structure conformation (that is to say continuous amino acid residue sequence) of natural insulin and polypeptide purifying, that separate of at least a biological property. Generally speaking, its meaning of term " insulin " comprises natural and synthetic insulin of deriving, comprise its sugared combining form, with and analog, comprise the polypeptide with one or more amino acid modified (disappearance, insertions or alternative), as long as they have kept at least 80% or the above therapeutic activity of total length insulin (before carrying out chemical modification with polymer hydrophilic, that non-natural exists as herein described) basically. Insulin of the present invention can be produced by the mode of any standard, includes but not limited to that pancreas extracts, restructuring is expressed and external polypeptide is synthetic. Natural or wild type insulin refers to the insulin that the amino acid sequence of the insulin that its amino acid sequence and occurring in nature are found is corresponding. Natural or wild type insulin can (namely separate from natural origin) or produce synthetically natively.

" cleavable on the physiology " or " degradable " key are the weak bonds that can react with water (namely being hydrolyzed) under physiological condition. Refer in the preferred case be less than about 30 minutes key at pH8 and 25 ℃ of lower hydrolysising half-lifes. The trend that key is hydrolyzed in water not only depends on the general type of the key that connects two central atoms, and depends on the substituting group that is combined on these central atoms. Suitable hydrolytically unstable or weak key includes but not limited to carboxylate, phosphate, acid anhydrides, acetal, ketal, acyloxy Arrcostab, imines, ortho position ester, peptide and oligonucleotides.

" hydrolysis-stable " connects or key refers to a chemical bond, in general is covalent bond, and it is basicly stable in water, that is to say under physiological condition, within one long period, any hydrolysis that can feel can not occur. The example of the key of hydrolysis-stable includes but not limited to following key: carbon-carbon bond (such as in aliphatic chain), ehter bond, amido link, urethanes etc. In general, the hydrolysis rate that shows under physiological condition of the key of hydrolysis-stable is less than about 1-2% every day. The hydrolysis rate of representational chemical bond can find in the most standard chemical textbook.

Comprise any water miscible polyalkylene oxide at this used " PEG " or its meaning of polyethylene glycol. In most typical situation, used PEG contains lower array structure among the present invention: " CH₂CH ₂O(CH ₂CH ₂O) _nCH ₂CH ₂-", wherein the practical structures of end group or whole peg moiety can change. A kind of PEG commonly used is the PEG of endcapped, and wherein PEG end generally is alkoxy grp such as methoxyl group (OCH by the sealing of the group of a relative non-activity₃), and another end is an oh group, it is easy to carry out chemical modification subsequently. For the preparation of the special PEG form of insulin bonder of the present invention, such as PEG branch, linear, bifurcated etc., will describe in more detail in the back.

" PEG-insulin bonder " refers to an insulin molecule (as defined above), covalently connect on it or combine at least one polyalkylene glycol moiety, but and the insulin active (for example natural insulin about 2% to about 100% or above biologically active) with any detection level.

When the polymer that relates to the hydrophilic non-natural existence of the present invention such as PEG, " nominal mean molecule quantity " refers to the quality mean molecule quantity of polymer, generally determined by aperture exclusion chromatography, light scattering or the intrinsic velocity in 1,2,4-trichloro-benzenes. Polymer of the present invention generally is polydisperse, has the low polydispersity less than about 1.05.

" lipophilic portion " is a group, when passing through a degradable or nondegradable key when hydrophilic polymer of the present invention is combined, is effective for the water-wet behavior that basically changes polymer and polymer-insulin bonder. Typical lipophilic group such as aliphatic acid can contain about 12 to 22 carbon atoms.

" basic non-immunogenic " of the present invention insulin bonder is compared the immunogenicity with minimizing with natural insulin. Immunogenicity can be by with the insulin administration mouse of PEG-insulin bonder with respect to unmodified, or preferably behind the rabbit, measure the titre of antibody and assess.

" alkyl " refers to hydrocarbon chain, and general length range is about 1 to 15 atom. Hydrocarbon chain preferably but need not be saturated can be chosen wantonly and contain other functional group in conjunction with thereon. Hydrocarbon chain can be side chain also can be straight chain. The example of alkyl comprises ethyl, propyl group, 1-methyl butyl, 1-ethyl propyl and 3-methyl amyl. In a preferred embodiment of the invention, contain an alkylating PEG, the particularly bond of the alkylating PEG of a linearity, referring to have one is not the bond of the moieties of aliphatic acid or other lipophilic portion.

" low alkyl group " refer to contain 1 to 5 carbon atom alkyl group, can be straight chain or side chain, for example methyl, ethyl, normal-butyl, isobutyl group, the tert-butyl group.

" absolute lung's bioavaliability " is that the drug dose (for example PEG-insulin bonder of the present invention) that is sent to mammal lung is compared with the natural insulin intravenous dosages and is absorbed and enters sanguimotor percentage. Comprise rat, dog, rabbit and monkey for the representative model system of measuring absolute lung's bioavaliability. From on the one hand, the PEG-analgesic composition that sucks of the present invention is characterized by lung's bioavaliability absolute in blood plasma or blood for about at least 20%, and common absolute lung's bioavaliability scope is from about 10% to 30% or higher. Generally speaking, according to the special properties of PEG-insulin bonder, bond of the present invention has at least one of approximately following absolute lung's bioavaliability: 10%, 12%, 15%, 18%, 20%, 22%, 25%, 30%, 32%, 35% or higher. Absolute lung's bioavaliability can be estimated by measuring PEG-insulin bonder composition by administration, instillation in the direct tracheae or sucking the rear absorption value that produces.

When relating to the half-life of PEG-insulin bonder, " allocated phase " refers to that insulin begins the stage that disappears fast from blood plasma. The slowly terminal or removing half-life in stage refers to the slow stage that insulin is eliminated from health.

" long-acting " insulin refers to effectiveness (i.e. level in the blood of the rising more than a reference value) about at least 6 hours of duration, in the preferred case about at least 8 hours insulin.

" repressed glucose level " refers to be suppressed in a reference value or the following blood sugar level (for example after using PEG-insulin bonder of the present invention) of basic horizontal.

" pharmaceutically useful salt " includes but not limited to amino-acid salt, salt with the inorganic acid preparation, such as chloride, sulfate, phosphate, hydrophosphate, hydrobromate and nitrate, or with the salt of organic acid preparation, such as malate, maleate, fumarate, tartrate, succinate, ethylsuccinate, citrate, acetate, lactate, mesylate, benzoate, ascorbate, tosilate, palmitate, salicylate and stearate and estolate, gluceptate (gluceptate) and Lactobionate (lactobionate). Similarly, contain pharmaceutically useful cationic salt and include but not limited to sodium, potassium, calcium, magnesium, aluminium, lithium and ammonium (ammonium that comprises replacement) salt.

" amino acid " refers to any compound that contains simultaneously an amino group and a carboxylic acid group. Although amino group usually appear at carboxyl functional group adjacent position on, it also can be positioned at any position of molecule. Amino acid also can contain other functional group, such as amino, thio group, carboxyl, carbamyl, imidazole radicals etc. Amino acid can be synthesized or natural formation, can use with the form of raceme or optical activity (D-or L-), comprises the enantiomer that contains various ratios.

" peptide " is comprised of two or more amino acid that couple together by peptide bond. Peptide can be the peptide of homology or the peptide of allos (namely being comprised of identical or different aforementioned amino acid residues), and its length can change between a hundreds of amino acid at two amino acid.

" dry powder " refers to generally contain the powder composition of not enough about 10% moisture.

" be suitable for lung transmit " composition refers to and can be atomized and be sucked by study subject, thus make the part of atomized particles arrive lung and penetrate into lower respiratory tract and alveolar in composition. Such composition is considered to " respirable " or " can suck ".

" atomizing " particulate is the liquid or solid particle that is suspended in the gas, generally is by activating (or startup) suction apparatus, produces such as the inhalator of Diskus, sprayer, metering or atomizer.

" emission dosage " or " ED " provide indication for the pharmaceutical preparation that a suitable inhaler device therefrom transmits after startup or dispersion event. More particularly, for dry powder formulations, ED is the tolerance of that take out and the percentage powder that sprays from the nozzle of suction apparatus from a UD bag. ED is defined as the dosage of suction apparatus transmission and the ratio of specified dosage (namely being placed on the powder quality of each UD in the suitable suction apparatus before startup). ED is a parameter of being determined by experiment, and device outside that is designed to modal patient's medication of normal operation is measured. Be mensuration ED value, the dry powder of specified dosage, generally the form with UD is placed in the suitable Diskus (for example in U.S. Patent No. 5,785, the inhalator of describing in 049, called after Inhalation Therapy System), starting drive radiation powder then. Extract out in then by vacuum from then on the mist cloud that produces being installed, and a tared filter that is connected on the device nozzle catches. The amount that arrives the powder of filter has formed emission dosage. For example, for the dosage that contains 5mg dry powder that is placed in the suction apparatus, if reclaimed the 4mg powder at above-mentioned tared filter after the powder emission, the emission dosage of dry powder formulations is so: 4mg (dosage of transmission)/5mg (specified dosage) * 100%=80%. For heterogeneous powder, the ED value is for providing indication from a suction apparatus transmission medicine rather than dry powder after starting, and it is based on the amount of medicine rather than the weight of total powder. Similarly, for MDI and atomizer delivery form, ED is corresponding to that take out from delivery form and the percentage medicine that sprays from the nozzle of suction apparatus.

" fine particle dosage " or " FPD " are defined as the mass percent of the powder particle of pneumatic particle diameter below 3.3 μ m, and be generally definite by measuring in the Anderson cascade impactor.This parameter can arrive patient's deep lung and provides an indication with the particulate percentage ratio of the composition that absorbs the drug capapie for having maximum potential.

" dispersible " or " dispersive " powder is meant that the ED value for about at least 30%, is more preferably 40-50%, and more preferably or even at least approximately 50-60% or higher powder.

" mass median particle diameter " or " MMD " are the tolerance of mean diameter, and this is because powder of the present invention generally is polydisperse (promptly being made up of the particle diameter in the certain limit).Although any technology commonly used all can be used for measuring mean diameter (for example ultramicroscope, light scattering, laser diffraction), measure by centrifugal sedimentation in the MMD of this report value.

The tolerance that " the pneumatic particle diameter of mass median " or " MMAD " are dispersed particulate pneumatic particle diameter.Pneumatic particle diameter is used to describe the sedimentation behavior of atomized powder, is the diameter that has the unit intensity spheroid of same sedimentation velocity in air with microgranule.Pneumatic particle diameter contains the physics size of the shape, density and the microgranule that have covered microgranule.At this used MMAD, unless otherwise, be meant the mid point or the intermediate value of the pneumatic particle size distribution of the atomized powder of determining by cascade impactor.

" pharmaceutically useful excipient or carrier " is meant and can chooses the excipient that is included in the present composition wantonly.The preferred excipient of the compositions that is used for sucking is that those can be brought into pulmonary, and to study subject, particularly the pulmonary of study subject does not have the excipient of obvious toxic-side effects.

" medicine effective quantity " or " physiology effective dose " is to need the amount of the PEG-insulin bonder that exists in the therapeutic combination described here to reach the target blood glucose level for the insulin level that expection is provided in blood flow.Amount depends on many factors accurately, factor of the composition of for example specific PEG-insulin, used transporter, therapeutic combination and physical property, prospective patients quantity, patient or the like can easily be determined according to the information that provides by those skilled in the art.

Polymer-insulin bonder that II, hydrophilic non-natural exist

Several exemplary PEG-insulin bonders have been prepared according to the present invention.Although Polyethylene Glycol is preferred polymer in conjugate of the present invention, the polymer that other is water miscible, hydrophilic, non-natural exists also can use.Other polymer that is suitable for using in the present invention comprises polyvinyl pyrrolidone, polyvinyl alcohol, polypropylene acyl group morpholine, poly- azoles quinoline and polyoxy ethylization polyhydric alcohol such as polyoxy ethylize glycerol, polyoxy ethylization sorbitol and polyoxy ethylization glucose.Also can use the polymer of from above-mentioned water-soluble polymer, selecting that contains subunit or subunit block.In addition, the copolymer of Polyethylene Glycol and polypropylene glycol also can use.In the preferred case, polymer of the present invention not fatty acids group or other lipophilic portion substantially.

Hereinafter set forth by carefully selecting one or more peg moieties, PEGization reagent, insulin PEGization site, PEGization condition and follow-up conjugate purification, can obtain to have the PEG-analgesic composition of the clinical character of expection (improved pharmacokinetics and/or drug effect character).The specific characteristic of PEG-insulin bonder of the present invention will be provided now.

The architectural feature of the conjugate of A, polymer and generation

PEG-insulin bonder of the present invention generally contains one or more PEG chains, and the molecular weight of each chain is from about 200 to about 40,000 dalton, in the preferred case from about 200 to about 10,000 dalton.In the preferred case, the mean molecule quantity that PEG had that uses among the present invention will be positioned at one of following scope: from about 200 to 10,000 dalton, and from about 200 to about 7,500 dalton, from about 200 to about 6,000 dalton, from about 200 to about 5,000 dalton, from about 200 to about 3000 dalton, from about 200 to about 2000 dalton, and from about 200 to about 1000 dalton.In embodiment 1-4, provide with having the example that molecular weight is the conjugate of 5,000 dalton, 2,000 dalton and 750 daltonian PEG preparations.

The PEG-insulin that preferably is administered into pulmonary will have molecular weight less than about 5000 dalton, preferably less than about 2000 dalton and even less than about 1000 daltonian peg moieties.In a specific embodiment of the present invention, the peg moiety in the PEG-insulin bonder has one of following mean molecule quantity: 200,300,400,500,600,750,1000,1500,2000,2500,3000,3500,4000 or 5000.In some cases, be not inclined to use the PEG of higher molecular weight, this is because they have the potential probability that insulin molecule is lost activity or reduce (embodiment 8) by the effectiveness of lung when pulmonary drug.

Because higher bioavaliability tends to select the PEG of lower molecular weight, but high-molecular weight PEG chain, for example mean molecule quantity is 5,000,10,000,15,000,20,000,25,000,30,000 or 40,000 dalton or higher PEG chain are although it is generally acknowledged the bioavaliability that has reduced natural insulin, but tend to increase the half-life, particularly in injectable preparation.That is to say that for a high-molecular weight PEG-insulin (for natural insulin) significantly improving of pharmacokinetic parameter such as area under a curve (AUC) can compensate its active loss.

As for the quantity of subunit, (the OCH that the PEG that the present invention uses generally contains ₂CH ₂) quantity of subunit is within following one or more scopes: 2 to about 900 subunits, from about 4 to about 200 subunits, from about 4 to about 170 subunits, from about 4 to about 140 subunits, from about 4 to about 100 subunits, from about 10 to about 100 subunits, from about 4 to about 70 subunits, from about 4 to about 45 subunits and from about 4 to about 25 subunits.

PEG-insulin bonder of the present invention can be mono-substituted (that is to say, PEG is attached to one singlely to has on reactive insulin site), disubstituted (have and be attached to two peg moieties on the reactivity site), trisubstituted or, even have polymer scale to be incorporated on the site more than three on the insulin molecule.Replace insulins in this single replacement, two replacement and three and also refer to PEG monomer, dimer and trimer respectively.In general bonded peg moiety is identical to polysubstituted insulin (referring to have the insulin that is covalently bonded in the peg moiety on two or more insulins site) on each reactivity site, although be not must be like this.That is to say to have above the PEG-analgesic composition that is attached to the peg moiety on the insulin of more than one types and can expect.For the present invention, preferred compositions is those compositionss that mainly contain monomer and/or dimer insulin bonder.It is shocking, have been found that non-site-specific PEG-analgesic composition (comprising the mixture with the PEG-insulin species that is covalently bound to the PEG on the more than one reactivity site) has pharmacokinetics and the drug effect character that is higher than natural insulin, particularly when at pulmonary administration (embodiment 11).

With regard to the position that PEG replaces, insulin molecule has several sites and is suitable for PEGization, more preferably amino sites in general, but this is optional.The specific insulin amino group that is suitable for PEGization comprises terminal GlyA1 of two N-and PheB1, and LysB29.These sites on the insulin molecule also are called as A1, B1 and B29 in this article respectively.The close electric activatory PEG that is used to be connected on the reactive amino group on the insulin comprises (Shearwater Corporation such as mPEG2-ALD, mPEG-succinyl phosphorons amino propyl acid, mPEG-succinimido butanoic acid, mPEG-CM-HBA-NHA, mPEG-benzotriazole carbonic acid, mPEG-acetaldehyde diethyl acetal, Huntsville, Alabama).

In one embodiment, a kind of compositions of the present invention can mainly contain (surpassing 90%) mono-substituted insulin, for example single A1 insulin, single B1 insulin or single B29 insulin.Such compositions can contain: 1) single A1 insulin, 2) mixture of single A1 insulin and single B1 insulin, or 3) mixture of single A1 insulin, single B1 insulin and single B29 insulin.In addition, compositions of the present invention can mainly contain disubstituted insulin, and is for example two-A1, B1-insulin or two-A1, B29-insulin or two-B1, B29-insulin or its any different combination.

In addition, compositions of the present invention can contain the mixture (being that PEG is combined in any combination of possible binding site) of different PEG-insulin bonders.With the amino sites on the insulin is example, compositions of the present invention can contain any or multiple in the following PEG-insulin bonder: single A1-PEG insulin, single B1-PEG insulin, single B29-PEG insulin, two-A1, B1-insulin, two-A1, B29-insulin, two-B1, B29-insulin or three-A1, B1, the B29-insulin.In one embodiment, preferably mainly contain monomer and dimeric compositions.Representational compositions can comprise monomer and dimer, the monomer of about at least 80% combination and the monomer and the dimeric PEG-insulin bonder mixture (as embodiment 5 and 6) of dimer or at least approximately 85-90% combination that contains about at least 75% combination.

PheB1 is the particularly preferred site of carrying out chemical modification in conjunction with PEG.Particularly in one embodiment, be used for PEG-insulin bonder compositions of the present invention, has such feature: no matter the sum of PEG-insulin species how in compositions, wherein about at least 70% B-1 site is by the PEG covalent bond (for example on the insulin, table 3A, embodiment 5).Other embodiment comprises following compositions, wherein on the insulin about at least 75% B-1 site by the PEG covalent bond or wherein on the insulin about at least 80% B-1 site by the PEG covalent bond or wherein on the insulin about at least 90% B-1 site by the PEG covalent bond.

It is shocking, the inventor have been found that the PEG-insulin random mixture (by at random rather than the fixed point PEGization prepare), when being administered into pulmonary, the insulin level that raises in the blood can be kept 6 hours at least, was to keep at least 8 hours after the administration or the longer time under the more typical situation.Such mixture has advantage; not only because their better pharmacokineticss and drug effect character; and because their the corresponding site-specific method of synthetic ratio simple more (do not need a plurality of synthesis steps, do not need to use blocking group, do not need multistep purification etc.).

On the natural insulin molecule, can comprise 2 C-ends, Arg22B, His10B, HisSA, Glu4A, Glu17A, Glu13B and Glu21B by other site that covalent bond PEG carries out chemical modification.

Except natural insulin, the non-natural insulin with one or more amino acid replacements, insertion or disappearance also can be used, and carries out chemical modification so that other sites can be used for connecting one or more peg moieties.This embodiment of the present invention is particularly useful for the PEGization site of introducing other customizations in insulin molecule, for example, is used to form the PEG-insulin that enzymolysis is had higher resistance.Such method provides higher motility, can be used for designing the insulin bonder of the optimization with required isostatic activity, stability, dissolubility and materia medica character.Although in insulin molecule, can suddenly change on any amount of site, promptly site-specific mutation, most preferred igf mutant body is that in preceding 4 aminoacid on the B chain any one replaced by a cysteine residues.Such cysteine residues can react with an activatory PEG with the mercapto groups specific reaction then, for example in U.S. Patent No. 5,739,208 and the open No.WO 01/62827 of international application in N-maleimide based polyalcohol or other derivant described.The sulfydryl selectivity PEG that is used in this specific embodiment of the present invention comprises the ramose maleimide of mPEG-(mPEG (MAL) ₂), the ramose maleimide of mPEG2-(mPEG2 (MAL) ₂), mPEG-maleimide (mPEG-MAL) and mPEG2-maleimide (mPEG2-MAL) (Shearwater Corporation).The structure of these activatory PEG is as follows respectively: mPEG-CONHCH[CH ₂CONH (CH ₂CH ₂O) ₂CH ₂CH ₂-MAL], mPEG2-lysine-NH-CH[CH ₂CONH (CH ₂CH ₂O) ₂CH ₂CH ₂-MAL] ₂, mPEG-MAL and mPEG2-lysine-NH-CH ₂CH ₂NHC (O) CH ₂CH ₂MAL.

If desired, also can use other sudden change of natural insulin sequence, to improve the biological activity of the PEG-insulin bonder that its biologic activity loses after PEGization.Such sudden change is that 8 threonine becomes histidine.Other sudden change can be at for example Diabetes Care, finds in 13 (9), 1990, and its content is drawn at this and is reference.

The PEG of Shi Yonging can have different structures in the present invention: linear, bifurcated, ramose, dumbbell shaped or the like.In general, PEG activates with a suitable activated group, is combined on one or more expections site of insulin molecule being suitable for.Activatory PEG at one end have a reactive group with insulin response.At this used term " joint ", its meaning comprises the activated group that is positioned at PEG end and insulin response, can further include other (the being generally inertia) atom between the peg moiety of polymer and terminal activated group, so that the preparation of activatory PEG is easy.Joint can contain any in the multiple atom, and still, preferred joint contains the methylene between PEG skeleton and terminal activated group, for example in mPEG-succinyl phosphorons amino propyl acid and mPEG-butanoic acid like that.Representational activatory PEG derivant and be to be widely known by the people in this area as the bonded method of insulin with these reagent and medicine, further description can be referring to Zalipsky, S. wait " Use ofFunctionalized Poly (Ethylene Glycols) for Modification of Polypeptides (Polyethylene Glycol of function of useization carries out peptide modified) " in " Polyethylene Glycol Chemistry:Biotechnical and BiomedicalApplications (Polyethylene Glycol chemistry: biotechnology and biomedical applications) ", J.M.Harris compiles, Plenus publishing house, New York (1992), and Advanced Drug Reviews, 16:157-182 (1995).

In a specific embodiment of the present invention, the peg moiety of conjugate lacks the effective one or more lipophilic groups of the water-soluble nature of remarkable modified polymer or polymer-insulin bonder.That is to say, the polymer of conjugate of the present invention or non-insulin part can contain one group of atom, compare them with hydrophilic atom and be considered to more lipophilic (for example having) from about 2 carbochains to 8-12 carbon atom, but, if the existence of so one or more groups is invalid to the hydrophilic nmature of remarkable change polymer or conjugate, so such part can be included in the conjugate of the present invention.That is to say that the feature of insulin bonder of the present invention itself is hydrophilic, rather than lipophilic or amphipathic.In general, the polymer moieties of an insulin bonder is before being attached to insulin, no matter whether contain lipophilic group, always have high hydrophile/lipophile difference (HLB) number.The HLB number is based on the percetage by weight of every type of group (hydrophilic or lipophilic) in the molecule, and the scope of its value is generally at about 1-40.The polymer that is used for conjugate of the present invention, must it is characterized by hydrophilic, no matter whether there are one or more lipophilic substituent groups.In one embodiment of the invention, the polymer moieties of polymer-insulin bonder is characterized by the HLB number greater than 25, more preferably under the situation greater than 30, or more preferably under the situation even greater than 35.In certain embodiments of the invention, lipophilic portion can exist, but this part is not positioned at an end of PEG chain in the preferred case.

The ramose PEG that is used for conjugate of the present invention is included in those that describe among the open WO96/21469 of international monopoly, and drawing specially at this with its full text content is reference.In general, ramose PEG is to represent that with general formula R (PEG-OH) n wherein R represents " core " molecule of central authorities, and n represents the number of arm.Ramose PEG has the core of central authorities, stretches out two or more PEG arms from it.In branched configurations, ramose polymer core has a single reactive site to combine with insulin.Be used for ramose PEG of the present invention and generally contain and be less than 4 PEG arms, under more preferably situation, contain and be less than 3 PEG arms.Ramose PEG provides some advantages: have single reactive site, compare with bigger denser polymer cloud with their linear PEG homologue and combine.A kind of PEG of branch of specific type can use (MeO-PEG-) _pR-X represents that wherein p equals 2 or 3, and R is central core structure such as lysine or the glycerol that is connected with 2 or 3 PEG arms on it, and any suitable functional group with the connection insulin that maybe can be activated that is activated of X representative.The particularly preferred PEG of branch is that (Shearwater Corporation, Alabama), it has the structure of mPEG-lysine-butanimide to mPEG2-NHS.

In another branched structure, the reactive group of " PEG dangles " can be with albumen along PEG skeleton positioning combination, rather than is combined in the end of PEG chain resembling in front the example.From the PEG skeleton reactive group that is used for bound insulin that extends out can be identical, also can be different.The PEG structure of dangling may be useful, but generally is not inclined to use, particularly for composition for inhalation.

In addition, the peg moiety of PEG-insulin bonder can contain the structure of a bifurcated, has a component at an end of polymer chain, also has two free reactive groups (or multiple of any 2) that are connected on the component to be used for bound insulin.The example of the PEG of bifurcated has description in the open No.WO 99/45964 of international monopoly, its content is drawn specially at this and is reference.The opposite ends that the Polyethylene Glycol of bifurcated also can be chosen wantonly at polymer chain comprises an alkyl or " R " group.More particularly, the general formula of the PEG-insulin bonder of bifurcated of the present invention is: R-PEG-L (Y-insulin) n, wherein R is an alkyl, L is the branch point of a hydrolysis-stable, and Y is a linking group, it is connected for providing chemical between the polymer of bifurcated and the insulin, and n is 2 multiple.L can represent one " core " group, and for example " CH-" also can contain longer atomic link.The example of L group comprises lysine, glycerol, tetramethylolmethane or sorbitol.In general, specific branch's atom is a carbon in the component.

In a specific embodiment of the present invention, be connected (Y) between the PEG of bifurcated and the insulin molecule is hydrolysis-stable.In a preferred embodiment, n is 2.With before reactive site on the insulin combines, suitable Y partly includes but not limited to active ester, active carbonic acid, aldehyde, Carbimide., isothiocyanic acid, epoxide, alcohol, maleimide, vinyl sulfone(Remzaol (vinylsulfone), hydrazides, two thiopyridines and iodoacetamide.The selection of suitable activated group depends on the purpose site that is combined on the insulin molecule, can easily be determined by this area professional and technical personnel.Corresponding Y group comes from the reaction of the appropriate reaction active site on activatory bifurcated polymer and the insulin in the PEG-insulin bonder that produces.For this area professional and technical personnel, the specific identity of so final connection is tangible.For example, if the bifurcated PEG of reaction contains activatory ester, as butanimide or maleimide ester, the connection by an amino sites on the insulin will produce the corresponding amide key.These special bifurcated polymer are attractive especially, are 2: 1 or higher conjugate because they provide the mol ratio of insulin and PEG.Such conjugate can not be blocked the Insulin receptor INSR site, and the motility in the design still is provided simultaneously, avoids for example enzymatic degradation of insulin-degrading enzyme with the protection insulin.

In a relevant embodiment, the PEG-insulin bonder of bifurcated of the present invention is by general formula R-[PEG-L (Y-insulin) ₂] _nExpression.In this case, R represents the central core structure that combines a PEG-pair-insulin bonder on it at least.Particularly, according to the present invention this on the one hand, preferred those bifurcated polymer, wherein n is selected from 1,2,3,4,5 and 6.Core R example of structure also can be derived from lysine, glycerol, tetramethylolmethane or sorbitol.

In another embodiment, in any representational structure provided herein, the chemical bond between insulin and the polymer branch point can be degradable (being hydrolytically unstable).In addition, in polymer backbone, can contain one or more degradable keys, so that produce PEG-insulin bonder in vivo with PEG chain shorter than the conjugate of beginning administration.This selectable characteristics of polymer conjugates can be learned character to its final expected drug after the conjugate administration additional control is provided.For example, can a kind of big conjugate of administration (be to be connected with one or more high-molecular weight PEG chains on the conjugate with relative inertness, for example one or more molecular weight are greater than about 10,000 PEG chain, conjugate biologically active not substantially wherein), then it or in lung or in blood flow, be hydrolyzed, produced a kind of bioactive conjugate that contains some initial PEG chain that exists.Adopt this mode, can more effectively be fit to the character of PEG-insulin bonder to a certain extent.For example, initial polymer conjugates is when at first by preferably but need not inhalation the time, its absorption may be slow.When the degradable key of hydrolysis in vivo after the cracking, free insulin (depending on the position of degradable key) or the insulin that has a little polyethylene labelling on it just are released, and they are easier to absorb and/or circulate in blood by pulmonary.

A feature of this embodiment of the present invention is, complete polymer conjugates before the hydrolysis, degraded is very slow after administration, so that the hydrolysis of the key of cleavable can be controlled biologically active insulin effectively and be discharged at a slow speed in the blood flow, this is opposite with insulin first enzymatic degradation before it is discharged in the systemic circulation.

The key of cleavable under physiological condition that is fit to includes but not limited to ester, carbonic ester, carbamate, sulfuric ester, phosphate ester, acyloxy Arrcostab, acetal and ketal.Such conjugate should have the key of cleavable under the physiological condition, and it is stable when storage and administration.For example, the key-insulin bonder of PEG-cleavable, producing in the last ingredient, if used suitable administration vehicle in being dissolved in wherein, and no matter approach how in administration, all should be kept its integrity.

Generality as the front is described, more particularly, being used for the PEG-insulin bonder with biodegradable key of the present invention is represented by following structure: PEG1-W-PEG2-insulin (wherein PEG1 and PEG2 can be identical also can be different) or PEG-W-insulin, wherein W represents the biodegradable key a little less than in the of.These conjugates contain (can be cracked) the PEG arm that can remove in vivo or the part of PEG arm.The insulin of these special modifications is general essentially no biological activity when complete, this or because the size of the complete peg moiety of molecule or because PEG chain sterically hindered to the avtive spot on the insulin molecule.But such conjugate is cleaved under physiological condition, discharges the PEG-insulin that insulin maybe can absorb the biologically active that enters systemic circulation by for example pulmonary.In first kind of example structure, PEG1 part can have any in the multiple different structure that this paper discusses, and general molecular weight is for about at least 10,000, so as conjugate after administration not by fast Absorption.The PEG2 part preferred molecular weight of molecule is less than about 5000 dalton, under more preferably situation less than 2000 dalton, and under more preferably situation even less than 1000 dalton.Quote second example structure PEG-W-insulin, generally about at least 10,000 dalton of the molecular weight of its peg moiety or higher.

In another particular of the present invention, the PEG-insulin bonder has a kind of structure of dumbbell shaped, and wherein two insulin parts are connected with each other by the PEG of central authorities.Particularly, such conjugate can represent that wherein Y and Z are the linking groups of hydrolysis-stable with " insulin-Y-PEG-Z-insulin " structure, is used for insulin and peg moiety are coupled together.In a specific embodiment, Z was an activatory sulfone before combination, be suitable for insulin on mercapto groups (for example cysteine) reaction.In addition, Y and Z can be any being suitable for and the covalently bound group of insulin.Other example is referring to U.S. Patent No. 5,900,461, and its content is drawn specially at this and is reference.

The list or the dual functional PEG that are used to prepare conjugate of the present invention that other is representational to have linearity or a branched structure can buy from Shearwater Corporation (Alabama).The structure of legend has description in the calendar year 2001 of Shearwater catalogue, title is " Polyethylene Glycol and the derivant that are used for biomedical applications ", and its content is drawn specially at this and is reference.

B, preparation

PEG is connected to reaction condition on the insulin depends on used specific PEG derivant, be attached to site on the insulin and the particular type (being lysine and cysteine) of reactive group, required PEGization degree etc. and change, those skilled in the art can easily determine.

In the more detailed in the back example, the synthetic of conjugate of the present invention can be (embodiment 1,2 and 4) of fixed point, also can be (embodiment 3) at random.The PEG activated group that is fit to react with insulin amino group (for example GlyA1, PheB1, Lys29B) is tresylate, aldehyde, epoxide, carbonylic imidazole, activated carbon acid esters (for example succinimdyl carbonate), acetal and active ester for example N-hydroxy-succinamide (NHS) and the deutero-PEG of NHS-.Wherein reactive the strongest is PEG carboxymethyl-NHS, nor-leucine-NHS and succinimidyl carbonate.Other PEG reagent that is used for bound insulin comprises PEG-succinimido succinic acid and propanoic acid.Be applicable to PEG active ester of the present invention, for example have the PEG active ester of single propanoic acid or butanoic acid part, in U.S. Patent No. 5,672, description is arranged in 662, drawing with its full content at this is reference.The specific active ester that is used to prepare conjugate of the present invention comprises mPEG-succinyl phosphorons amino propyl acid and mPEG-succinimido butanoic acid (embodiment 1-4).

For the suitableeest experiment condition of a particular combination thing, in general can easily determine by those skilled in the art by conventional experiment.

On the mercapto groups that is attached to insulin, the reactive group that is suitable for activated PEG-polymer comprises vinyl sulfone(Remzaol, iodoacetamide, maleimide and dimercapto-adjacent pyridine.Particularly preferred reagent comprises PEG vinyl sulfone(Remzaol and PEG-maleimide.Other is used for representative vinyl sulfone(Remzaol of the present invention in U.S. Patent No. 5,739, description is arranged in 208, and its content is drawn specially at this and is reference.

In some cases, compositions selectivity of the present invention contains the insulin of PEGization, and promptly the conjugate of Chan Shenging is being a homogenizing basically aspect position and the PEGization degree.That is to say that the site selectivity of amino group or fixed point PEGization can produce an insulin bonder compositions, wherein, for example combine a peg moiety on the PheB1 mainly at the expection target site.Depend on the PEGization site of expection; may need a kind of protection/go to protect synthesis strategy, for example by using a blocking group for example t-BOC (tert-butoxycarbonyl) or two-BOC (dibutoxy carbonyl) to prevent the PEGization of non-target response active site in the insulin molecule.Other amido protecting group that is fit to comprises benzyloxycarbonyl group (CBZ), trityl derivative for example trityl (Tr), dimethoxytrityl (DMTr) etc.Other blocking group for example encircles diacyl group or nitrobenzophenone sulfenyl (Nps) and also confirms to can be used for protecting amido functional group.The example of the synthetic a kind of 5K-PEG-analgesic composition of fixed point is provided among the embodiment 1 and 2.

Thisly be used to provide the fixed point of insulin bonder of the present invention can be created in the compositions that highly replaces on the specific reactive site of insulin molecule in conjunction with chemistry.Then, if desired, it is the compositions of pure list or dual functional PEG-insulin basically that these compositionss can be further purified to provide.

Basically pure PEG-analgesic composition is meant to detect according to following any analytical method and wherein contains about at least 90% purity, in the preferred case the PEG-insulin bonder of about at least 95% purity.Just in this point, purity is meant the content of PEG-insulin bonder.That is to say that the PEG-insulin bonder of about at least 90% purity contains the PEG-insulin bonder species of about at least 90% weight, and all the other nearly 10% representatives not the impurity of PEG-insulin bonder.PEG-insulin bonder of the present invention generally uses one or more purification techniques to carry out purification, for example ion-exchange chromatography, aperture exclusion chromatography, affinity chromatograph, hydrophobic interaction chromatography and reversed phase chromatography.The overall homogeneity of the PEG-insulin that obtains (quantity of the insulin of existence-PEG form) can be assessed by using one or more following methods: chromatography, electrophoresis, mass spectrum and particularly MALDI-MS and NMR (Nuclear Magnetic Resonance) spectrum (NMR).A kind of method of useful especially identification insulin decorating site is anti-phase high pressure liquid chromatography (RP-HPLC) peptide mapping, and coupling has an insulin human USP identity check (embodiment 6) of using endo protease Glu-C.

The special part of C, PEG-insulin bonder

According to one aspect of the present invention, provide the PEG-insulin bonder that is suitable for pulmonary administration compositions.By data in the body of embodiment 7-11 as can be seen, PEG-insulin bonder of the present invention when being administered into pulmonary, has pharmacokinetics and the drug effect character higher than natural insulin.Show, can be with molecular weight up to 5,000K to 10,000K or higher PEG modify insulin, still can keep activity simultaneously.The activity of a representational PEG-insulin bonder 5K-PEG-insulin is described in embodiment 7.In addition, from embodiment provided herein as can be seen, have average molecular weight range from 750 dalton to 2000 dalton, exemplary PEG-insulin bonder to 5000 daltonian PEG chains, when by vein and pulmonary administration, biologically actives all, and when pulmonary administration, be not trapped in the lung basically, as by can detected serum insulin levels indicated, and can produce effectively has significantly inhibition (embodiment 7 to 11) to glucose level, in some cases, the persistent period of this inhibition obviously is longer than and uses the viewed persistent period of natural insulin.In addition, at this PEG-insulin bonder that provides, when at pulmonary administration, very fast (after administration in 1 hour) comes into force.Table 13 provides the pharmacokinetics of example PEG-analgesic composition of the present invention and the summary of drug effect parameter.

In general, PEG-analgesic composition of the present invention will have one or more following characteristics.PEG-insulin bonder of the present invention has been kept the specific activity of measurable degree at least.That is to say that PEG-insulin bonder of the present invention will have natural insulin from about 2% to about 100% or more specific activity.In a preferred embodiment of the invention, the PEG-insulin bonder will have the natural insulin at least 10% or the more biologic activity of unmodified, and non-immunogenic basically.In the preferred case, the biological activity of conjugate of the present invention is a natural insulin bioactive about 5% to about at least 20% or higher.The bioactive sign of conjugate of the present invention can for example produce corresponding pharmacokinetics and/or drug effect data by glucose in the monitoring of blood and insulin level indirectly, or is undertaken by RIA (radioimmunoassay).

As for the insulin concentration in the serum after the PEG-insulin bonder being administered into pulmonary for example, conjugate described here generally goes out peak (promptly reaching the peak of Cmax (Cmax) or concentration curve) after administration about 2 to 8 hours, more generally at about about 3 to 6 hours.In addition, the insulin of chemical modification of the present invention particularly at this Insulin Glargin that provides, is compared with natural insulin, aspect providing the glucose that can measure to reduce effect and keep two of insulin concentrations in long period, all is effective.More particularly, during by pulmonary administration, the PEG-insulin bonder will show about at least 6 hours of the insulin level (being higher than basis or baseline values) of rising, at least 8 hours in the preferred case after administration.In the preferred case, during by pulmonary administration, the extended period of the PEG-insulin bonder will produce the blood insulin horizontal exceeding that raises after administration at least 9 hours, 10 hours, 12 hours or at least 14 hours, wherein after administration, in blood flow, can detect the insulin bonder that is higher than baseline values in such extended period.The representative compositions that can show these features is provided in an embodiment.

As previously mentioned, insulin bonder of the present invention is effective for the blood sugar lowering level.Look at that now compositions of the present invention suppresses the ability of blood glucose, during by pulmonary administration for example, PEG-insulin bonder of the present invention can effectively be suppressed at blood sugar level below the foundation level at least 6 hours after the administration.Under more specific situation, PEG-analgesic composition of the present invention can effectively be suppressed at blood sugar level below the foundation level at least 8 hours after the administration, and under the preferable case at least 10 hours, or more preferably at least 12 hours or longer time under the situation.

In addition, PEG-insulin preparation of the present invention shows the absolute pulmonary bioavaliability that is higher than natural insulin.Particularly, this provide the PEG-insulin preparation have natural insulin at least about 1.2 times absolute pulmonary bioavaliability, at least about in the preferred case 1.5 times to natural insulin, more preferably exceed about 2 times than natural insulin at least under the situation, perhaps more preferably exceeding about 2.5 times or 3 times at least under the situation.(table 13 provides illustrative result).

III, preparation

Polymer of the present invention-insulin bonder compositions can be individually dosed, also can be with the form administration of treatment/pharmaceutical composition of containing other excipient, solvent, stabilizing agent etc., and this depends on the particular form and the dosage form of administration.This conjugate can parenteral or parenteral external administration.That concrete route of administration comprises is oral, rectum, buccal, part, nose, eye, subcutaneous, intramuscular, intravenous, percutaneous and pulmonary.More preferably parenteral and pulmonary route.

For mammal and preferably people's administration, pharmaceutical preparation generally contains at least a PEG-insulin bonder of the present invention and one or more pharmaceutically useful carriers, and particularly for pulmonary's compositions, this is more detailed description in the back.The preparation of the present invention that for example is used for parenteral, prevailing is liquid solution or suspension, and the inhalable formulations that is used for pulmonary administration is generally liquid or powder, wherein is generally powder under the preferable case.The analgesic composition of the chemical modification of the present invention of other less employing comprises syrup, emulsifiable paste, ointment, tablet etc.

The preparation of insulin and corresponding dosage will change along with the biological activity concentration of the insulin that uses.Injectable insulin measures with USP insulin units and the human unit of USP insulin (U); The insulin of a unit equals in the rabbit of fasting blood sugar level reduced to the required amount of insulin of 45mg/dl (2.5mM).The concentration range of typical insuline pro injection preparation is 30 to 100 units/mL, is approximately every milliliter of 3.6mg insulin.In patient, to reach expection physiological effect required amount of insulin and not only change, and change along with the intensity of used insulin and specific type along with the concrete situation of patient and disease (for example I type and type ii diabetes) thereof.For example, the dosage range of regular insulin (effect type soon) for every day per kilogram of body weight use from about 2 to 0.3U insulins.From one side, compositions of the present invention can make the fasting serum glucose level reach between about 90 to 140mg/dl in the patient of experience treatment effectively, and value after meal is lower than about 250mg/dl.To those skilled in the art,, can determine accurate dosage, and can easily adjust according to the result of periodicity glucose monitoring in conjunction with pharmacokinetics and pharmacodynamics to the used definite insulin bonder of specific route of administration.

The scope that can suck the single dose (on every suction basis once) of insulin bonder preparation generally is to the 15mg insulin bonder from about 0.5mg, wherein generally in about 1 to 10 time is breathed, reach required accumulated dose, under the preferable case in about 1 to 4 time is breathed.On average, the peg insulin accumulated dose of each medication phase by inhalation is that about 10U arrives about 400U, and each single dose or unit dosage form (sucking corresponding to single) contain about 5U to 400U.

The inhalable formulations of A, chemically modified insulin

As mentioned above, a kind of preferred route of administering of insulin bonder of the present invention is to be drawn into pulmonary.Now concrete preparation composition, character and doser will be described more fully.

The amount of insulin bonder in the preparation is to transmit the insulin of treatment effective dose of per unit dosage to reach the therapeutic effect of at least a natural insulin, is about to blood sugar level and is controlled near the necessary amount of the ability of normal blood glucose.In practice, this will depend on the order of severity, the patient's of concrete insulin bonder, its activity, the diabetic symptom that will treat population, stability of formulation etc. and extensively change.Compositions generally contains the PEG-insulin from about 1% weight to about 99% weight, be typically and contain from about 2% conjugate to about 95% weight, more typical is the conjugate that contains from about 5% to 85% weight, also depends on the relative quantity of the excipient/additive that comprises in the compositions simultaneously.More particularly, a kind of PEG-insulin of percentage ratio below compositions generally contains at least: 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% weight or higher 10%.In the preferred case, it is about at least 60% that powder composition will contain, for example from the PEG-insulin of about 60% to 100% weight.Should be understood that the insulin that can mix more than one in the preparation described here, the combination of using two or more insulins or insulin and other activating agent is got rid of in the use of term " medicament " or " insulin " by no means.(for example, a kind of illustrative PEG-insulin preparation can also contain natural insulin).

A.1, excipient

In most of the cases, compositions of the present invention will comprise one or more excipient.Preferably the carbohydrate excipient can use separately also and can be used in combination with other excipient or additive.The representative carbohydrate that is used for the present composition comprises sugar, the derived carbohydrate for example sugar and the glycopolymers of sugar alcohol, aldonic acid, esterification.The example that is applicable to carbohydrate excipient of the present invention for example comprises, monosaccharide such as fructose, maltose, galactose, glucose, D-mannose, sorbose etc.; Disaccharide such as lactose, sucrose, trehalose, cellobiose etc.; Polysaccharide such as Raffinose, melezitose, maltodextrin, glucosan, starch etc.; And sugar alcohol such as mannitol, xylitol, maltose alcohol, lactose, xylitol Sorbitol (glucitol), pyrans glycosyl Sorbitol, inositol etc.Non-reducing sugar preferably, can form when mixing with insulin bonder is the sugar of the amorphous or glassy phase done basically, and (for example Tgs is higher than 40 ℃ to have the sugar of high relatively Tgs, be higher than 50 ℃ in the preferred case, more preferably be higher than 60 ℃ under the situation, and more preferably be higher than 70 ℃ under the situation, Tgs is 80 ℃ or higher under the most preferred case).

Other excipient comprises aminoacid, peptide and special contains 2-9 amino acid whose oligomer, is preferably the 2-5 aggressiveness, and polypeptide, and they can be of the same race or xenogeneic.Representational aminoacid comprises glycine (gly), alanine (ala), valine (val), leucine (leu), isoleucine (ile), methionine (met), proline (pro), phenylalanine (phe), tryptophan (trp), serine (ser), threonine (thr), cysteine (cys), tyrosine (tyr), aspartic acid (asp), glutamic acid (glu), lysine (lys), arginine (arg), histidine (his), nor-leucine (nor), and their modified forms.A particularly preferred aminoacid is leucine.

But what other was preferably used as excipient in composition for inhalation is dipeptides and the tripeptides that contains two or more leucyl residues, this is described in the International Patent Application PCT/US00/09785 of Inhale Therapeutic.System (Inhale Therapeutics Systems, Inc), and drawing in full with it at this is reference.

Have the glass phase inversion temperature be higher than about 40 ℃, more preferably be higher than under the situation 50 ℃, more preferably under the situation even to be higher than the dipeptides and the tripeptides that are higher than 70 ℃ under 60 ℃ and the most preferred case also be preferred.

Other be used for of the present invention can enhanced stability and the peptide of aerosol performance be 4 aggressiveness and 5 aggressiveness that contain above-mentioned amino acid whose any combination, although because the limited and less use of they dissolubility in water.Under more preferably situation, this 4 aggressiveness or 5 aggressiveness contain two or more leucine residues.Leucine residue can occupy any position in the peptide, and simultaneously other (being non-leucyl) amino acid position is occupied by above-mentioned any aminoacid, as long as at least about 1mg/ml of 4 aggressiveness that produce or the dissolubility of 5 aggressiveness in water.In the preferred case, the non-leucylamino acid in 4 aggressiveness or 5 aggressiveness is hydrophilic amino acid, lysine for example, thus increased the dissolubility of peptide in water.

Polyamino acid particularly contains any amino acid whose those polyamino acids described here, also is suitable for using used as stabilizers.Preferred polyamino acid is for example poly-D-lysine, polyglutamic acid and poly (lysine, alanine).

Other can be used for the excipient of this compositions and method and additive and comprises but be not limited to albumen, non-biological polymer and biopolymer that they can occur with form alone or in combination.The excipient that is fit to provides in open No.WO96/32096 of the international monopoly of Inhale Therapeutic Systems and No.WO 98/16205.Preferred excipient has glass phase inversion temperature (Tg) and is higher than about 35 ℃, is higher than about 40 ℃ under the preferable case, more preferably is higher than about 45 ℃ under the situation, is higher than about 55 ℃ under the most preferred case.

The example of albumen excipient comprises albumin for example human serum albumin (HAS), recombined human albumin (rHA), gelatin, casein, hemoglobin etc.Compositions also can contain buffer or pH regulator agent, and is general but need not organic acid or the salt of alkali.Representational buffer comprises the salt of organic sour lime acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid or phthalic acid.Other buffer that is fit to comprises Tris, tromethane hydrochloric acid (tromethamine hydrochloride), boric acid, phosphoglycerol and phosphoric acid.Aminoacid such as glycine also are suitable for.

Compositions of the present invention can also comprise other polymeric excipient/additive, for example polyvinyl pyrrolidone, deutero-cellulose such as hydroxy methocel, hydroxyethyl-cellulose and hydroxypropyl emthylcellulose, Ficoll (a kind of polymer sugar), hetastarch (HES), dextrate (for example cyclodextrin such as 2-hydroxypropyl-beta-schardinger dextrin-and sulfo group butyl ether-beta-schardinger dextrin-), Polyethylene Glycol and pectin.

Compositions can also comprise flavour enhancer, odor mask, inorganic salt (as sodium chloride), antibacterial (as benzalkonium chloride (benzalkonium chloride)), sweeting agent, antioxidant, antistatic additive, surfactant is (as polysorbate such as polysorbas20 and Tween 80, and the nonionic surfactant Pluronic (Pluronics) that derives from BASF is as F68 and F88), the sorbitan alcohol ester, lipid (for example, phospholipid such as lecithin and other phosphatidylcholine, although PHOSPHATIDYL ETHANOLAMINE is not in the preferred case with the form of liposome), fatty acid and fatty ester, steroidal (as cholesterol) and chelating agen are (as EDTA, zinc and other such cation that is fit to).The back has been described in more detail and has been used some disubstituted phosphatidylcholine to produce foraminous microstructure (being the foraminous microsphere of hollow).Other is applicable to the drug excipient of compositions of the present invention and/or additive " the The Science ﹠amp at Remington; Practice ofPharmacy (pharmaceutical science with put into practice) " the 19th edition, Williams ﹠amp; Williams publishing house, nineteen ninety-five and " Physician ' s Desk Reference (reference of doctor's desktop) " the 52nd edition, MedicalEconomics publishing house, Montvale, NJ lists in (1998).

In one embodiment, compositions of the present invention can not contain transparent agent, and it may cause stimulation, and is deleterious when high concentration, and absorption strengthens necessary and this high concentration normally provides significantly.The concrete reinforcing agent that can not be included in the present composition is reinforcing agent such as deoxycholic acid, polyoxyethylene lauryl ether-9 (Laureth-9), DDPC, glycocholate and the fusidinic acid (fusidate) of detergent class.But; some reinforcing agent; for example those protection insulins are avoided the reinforcing agent of enzymatic degradation; as protease and peptidase inhibitors such as the agent of α-1 protease inhibitor, captopril (captropril), thiorphan and hiv protease inhibitor; in certain embodiments of the invention, can be included in the PEG-insulin preparation of the present invention.In another embodiment, PEG-insulin bonder of the present invention can not contain liposome, lipid matrix and encapsulants.

Usually, pharmaceutical composition of the present invention contains from about 1% excipient to about 99% weight, contains in the preferred case from the excipient of about 5% to 98% weight, is more preferably containing from the excipient of about 15% to 95% weight under the situation.Under more preferably situation, spray-dired compositions contains the excipient of from 0 to 50% weight, more preferably under the situation, contains the excipient of from 0 to 40% weight.In general, wish in final pharmaceutical composition, to contain high insulin concentration.Generally, the optimal dose of excipient/additive is determined by experiment, the compositions (scope from low to high) that promptly contains different figuration dosage by preparation, detect the MMAD and the dispersibility of the chemistry of PEG-insulin and physical stability, pharmaceutical composition, further explore then and obtain the suitableeest aerosol performance, simultaneously to the dosage range of the stable non-evident effect of insulin.

A.2, preparation dry powder

The dry powder formulations that contains the PEG-insulin bonder of the present invention can preferably adopt spray-dired method by any dry technology preparation.The spray drying of preparation is at for example " Spray Drying Handbook (spray drying handbook) " the 5th edition, K.Masters, JohnWiley ﹠amp; Sons publishing house, NY, NY (1991) and Platz have general description among open No.WO 97/41833 (1997) of the international monopoly of R. etc. and the No.WO 96/32149 (1996), and its content is drawn at this and is reference.

The solution of PEG-insulin bonder is at conventional spray driers, and for example those carry out spray drying from the exsiccator of commercial supplier such as Niro A/S (Denmark), Buchi acquisitions such as (Switzerland), obtain a kind of dispersible dry powder.The spray-dired optimal condition of PEG-insulin solutions changes along with the preparation composition, generally is determined by experiment.The gas that is used for spray-dried materials generally is air, although noble gas such as nitrogen or argon are also applicable.In addition, it is suitable not cause by being degraded to of the PEG-insulin of spray material to be used for the temperature of entrance and exit of gas of dry institute spray material.Such temperature is determined by experiment that generally although under normal conditions, the temperature range of inlet is from about 50 ℃ to about 200 ℃, and the temperature range of outlet is from about 30 ℃ to about 150 ℃.Preferred parameter comprises atomizing pressure from about 20 to 150psi, in the preferred case from about 30-40 to 100psi.General used atomization pressure is one of following (unit is psi): 20,30,40,50,60,70,80,90,100,110,120 or higher.

Respirable PEG-analgesic composition with feature described herein also can be according to the method production of describing among the WO 99/16419, some preparation composition is carried out drying, thereby form foraminous microstructure powder, the full content of this patent draws at this and is reference.Foraminous microstructure powder generally contains the microsphere of the dried hollow of spray, and the hole wall with relative thin forms big inner space.Foraminous microstructure powder can be dispersed in a kind of selected suspension media (for example non-water and/or use fluorizated foaming agent) with in dry prerequisite for stable peptizaiton.Use low-density relatively foraminous microstructure or minitype particle to reduce captivation between microgranule significantly, thereby reduced shearing force, increased the dispersibility of the flowability of the powder that produces, and reduced the caused degraded of layering by flocculation, precipitation or its stable dispersion.

In addition, the PEG-analgesic composition of pulmonary administration can contain granule light on the aerodynamic, as U.S. Patent No. 6,136, described in 295 like that.

Powder formulation of the present invention can also be by lyophilization, vacuum drying, spraying lyophilizing, supercritical liq processing (as the U.S. Patent No. 6 at Hanna etc., described in 063,138 like that), the evaporation drying method of air drying or other form prepares.

In another approach, the preparation method of dry powder can be with powder composition cohesion, the material screening more is globular condensation product and screening to obtain uniform product to obtain condensation product, nodularization to provide, this method is at for example Ahlneck, C. the International PCT that waits openly has description among the No.WO 95/09616 (1995), draws at this to be reference.

Dry powder also can mix by the preparation composition to dry powder form, grinding, screening or jet grinding prepare.

In a single day dry powder composite forms, and preferably remains in production, processing and storage process (promptly relative low humidity) under the drying condition.No matter use which kind of drying process, preferably will produce the height dispersible granules that can suck, described granule contains the insulin of chemical modification described here.

A.3, the feature of dry powder formulations

Powder of the present invention also has several characteristics, and wherein the most significant is following one or more features: (1) uniform height dispersibility, even after storage, also can keep; (2) little aerodynamic particle size (MMADs); (3) fine particle dose value height, promptly granularity is higher less than the percentage composition of 3.3 microns MMAD in the powder; These features all help to improve the tissue (being alveolar) that powder passes lower respiratory tract and are sent to the ability in the systemic circulation.These physical propertys that suck powder of the present invention are very important for the maximizing efficiency that these powder atomization is sent to deep lung, will describe more fully below.

Dry powder of the present invention is by the aerosolizable granulometric composition that can effectively penetrate in the lung.The particulate mass median particle diameter of the present invention (MMD) is less than about 20-30 μ m, or less than 20 μ m, or less than about 10 μ m, under the preferable case less than about 7.5 μ m, and more preferably under the situation less than about 4 μ m, even less than about 3.5 μ m, usually particle diameter be at 0.1 μ m in the scope of 5 μ m.Preferred powder is made up of from the microgranule of about 0.2 to 4.0 μ m MMD.In some cases, powder also contains for example lactose of the carrier particles that can not breathe, and these particle size that can not breathe are generally greater than about 40 μ m.

Powder of the present invention also has such feature, the pneumatic particle diameter of the mass median of its aerosol particle size distribution (MMAD) is less than about 10 μ m, MMAD is less than about 5 μ m under the preferable case, more preferably under the situation less than 4.0 μ m, under more preferably situation even less than 3.5 μ m, and under the most preferred case less than 3 μ m.The pneumatic particle size range of the mass median of powder on feature from about 0.1 to 10 μ m, under the preferable case MMAD from about 0.2 to 5 μ m, more preferably under the situation MMAD from about 1.0 to 4.0 μ m, under more preferably situation even from 1.5 to 3.0 μ m.The spray drying condition that little pneumatic particle diameter generally can be by will be the suitableeest combines with the selection of excipient and concentration and obtains.

Its feature of PEG-insulin powder of the present invention also is their density.The powder composition that is used to suck in general bulk density from about 0.1 to 10g/ cubic centimetre, under the preferable case from about 0.1 to 2g/ cubic centimetre, more preferably under the situation from about 0.15 to 1.5g/ cubic centimetre.

The moisture of powder generally is lower than about 20% weight, is usually less than about 10% weight, and is lower than about 5% weight in the preferred case.The moisture of the preferred powder of the present invention is lower than one or more in about following percentage by weight: 15%, 10%, 7%, 5% or 3%.The solid of such low moisture content tends to show advantages of higher stability when packing and storage.

In addition, spray drying process described here and stabilizing agent can provide highly dispersible PEG-insulin preparation effectively.For powder, the emission dosage (ED) of these powder is generally greater than 30%, usually greater than 40%.Under more preferably situation, the ED of powder of the present invention is greater than 50%, and often greater than 60%.

Compositions described here also has good stable, comprises chemical stability and physical stability two aspects, promptly passes through the aerosol performance after long-time.Generally speaking, aspect chemical stability, through after the spray drying, the degraded of the PEG-insulin bonder that comprises in the preparation generally is no more than about 15%.That is to say, powder will contain about at least 85% complete PEG-insulin bonder, at least about 90% or 95% complete conjugate in the preferred case is under more preferably situation even contain about at least 97% or more complete PEG-insulin.In the preferred case, the powder that spray-drying process produces contains and is less than about 10% total protein polymer, that is to say, and be monomeric form greater than the insulin of the chemical modification of 90% weight.

At the aerosol aspect of performance, compositions of the present invention is characterized by, and when store 3 months under environmental condition after, it is about 20% that the reduction of emission dosage generally is no more than, and is no more than approximately 15% in the preferred case, and more preferably is no more than about 10% under the situation.

A.4, the administration of compositions

The transmission of PEG-insulin preparation described here can be used any suitable Diskus (DPI), promptly utilizes patient's the air-breathing suction apparatus that dry-powder medicament is transported to pulmonary as vehicle.Wherein preferably suck the powder inhaler of Inhale Therapeutic System, as at Patton, the U.S. Patent No. 5 of J.S. etc., 458,135, October 17 nineteen ninety-five, Smith, A.E. the U.S. Patent No. 5,740,794 that waits, on April 21st, 1998 and Smith, A.E. the U.S. Patent No. 5,785,049 that waits, describe in 28 days July in 1998, draw at this and be reference.When by such device administration, mealy medicine is placed in the accepter, this accepter has a lid that can pierce through or other enterable surface, be the packing or the box of rigid foam material liner under the preferable case, in accepter, can contain single dosage unit or a plurality of dosage unit.At for example Parks, the open WO of the international monopoly of D.J. etc. has described the method easily of the dry powder pharmaceutical of dosing being inserted a large amount of cavitys (being unit dose packaging) in 6,97/41031,1997 on November, draws at this to be reference.

Other dry powder dispersal device that is used for the dry powder pulmonary administration is included in for example Newell, R.E. 129985,1988 years JIUYUE of the European patent No.EP that waits 7 days, Hodson, the European patent No.EP472598 of P.D. etc., on July 3rd, 1996, Cocozza, S. the European patent No.EP467172 that waits, on April 6th, 1994 and Lioyd, the U.S. Patent No. 5 of L.J. etc., 522, those that describe in 4,385,1996 on June draw at this and to be reference.Other suction apparatus that is suitable for transmitting PEG-insulin dry powder is " TURBUHALER " of Astra-Draco for example.Such device is at Virtanen, the U.S. Patent No. 4,668 of R., on May 26th, 218,1987, Wetterlin, the U.S. Patent No. 4 of K. etc., 667, on May 26th, 668,1987 and Wetterlin, the U.S. Patent No. 4 of K. etc., 805, be described in detail in 21,811,1989 on February, all draw at this and be reference.Other device that is fit to comprises Diskus such as Rotahaler  (Glaxo), Discus  (Glaxo), Spiros ^TMInhaler (DuraPharmaceuticals) and Spinhaler  (Fisons).Other suitable device has used a piston that air is provided, both can be used for pressing from both sides normal powder medicine, with air by the carrier screen cloth from the screen cloth medicament of kicking up, also can in a mixing chamber, air be mixed with powder medicine, nozzle by device imports patient with powder then, for example at Mulhauser, and the U.S. Patent No. 5 of P. etc., 388, in 572,1997 on JIUYUE 30, describe, draw at this and be reference.

The PEG-analgesic composition that can suck also can use a kind of metered dose inhaler (MDI) of pressurization to come administration, Ventolin  metered dose inhaler for example, the medicine dissolution that it contains or be suspended on the materia medica in the inert liquid propellant, for example Chlorofluorocarbons (CFCs) or fluorohydrocarbon, as U.S. Patent No. 5 at Laube etc., on June 14th, 320,094,1994 and Rubsamen, R.M. the U.S. Patent No. 5 that waits, described in 672,581 (1994), all draw at this and to be reference.

In addition, PEG-insulin described here can be dissolved or suspended in solvent, in water or saline, passes through atomized medicine introducing then.The aerosol apparatus that transmits atomized soln comprises AERx ^TM(Aradigm), Ultravent  (Mallinkrodt), Pari LC Plus ^TMOr Pari LC Star ^TM(Pari GmbH, Germany), De Vilbiss Pulmo-Aide and Acorn II  (MarquestMedical Products).

As previously mentioned, PEG-insulin bonder described here also can be by intravenous injection, or under the less situation by intramuscular or subcutaneous injection and parenteral.The accurate composition of these preparations can easily be determined by those skilled in the art.The preparation type that is suitable for parenteral comprises solution that remarks penetrate, use before with the dry powder of solvent, suspension that remarks are penetrated, use before with the blended insoluble dry composition of medium, administration before need the Emulsion or the liquid concentrate that dilute.For example, the Injectable solution of PEG-analgesic composition of the present invention can comprise the compositions that is dissolved in aqueous medium such as sodium-chloride water solution, ringer solution, glucose injection, newborn acidifying ringer solution etc., and can comprise one or more above-mentioned pharmaceutically useful compatibility excipient or additives.

IV, purposes

Compositions of the present invention when by any suitable route of administration, is preferably suction or injection, when being administered into mammalian subject with the treatment effective dose, can be used for treating diabetes, particularly I type or type ii diabetes.

It is reference that all articles in this reference, books, patent and other publication all draw in full with it.

The following examples are for example understood scope of the present invention, but plan anything but scope of the present invention is limited.

Embodiment

Materials and methods

Polyethylene glycol reagents derive from Shearwater company (Huntsville, Alabama).

Insulin human derives from Diosynthm Inc.

Embodiment 1

Two-N ^{α A1}, N ^{ε B29}Synthesizing of-t-Boc-insulin

The main compositions of being made up of the insulin of single PEGization is according to embodiment 1 and 2 described locus specificity modes, and 5,000 daltonian Polyethylene Glycol of usage example linearity prepare.

The insulin of two protections is at first as following method preparation.602mg insulin human (0.103mmol) is dissolved in the 3.0mL anhydrous dimethyl sulfoxide (DMSO) that contains 166 μ L triethylamines.In insulin solutions, add 50 μ L, two-tert-butyl group-bicarbonate (0.215mmol).Room temperature was placed after 60 minutes, and reactant liquor is poured in the 240mL acetone, and the HCl that adds 3 6M then is with initial flocculation.Precipitation is passed through isolated by filtration, and dry in a vacuum.Product is used the preparation HPLC purification, uses Waters 25 * 100mm C18 post (particle mean size 15 μ m, aperture 100A).The deionized water mixture of acetonitrile and 0.1%TFA is as eluent, elution speed 3.0mL/min.Collect product, distillation is to remove acetonitrile, lyophilization then.Output is 164.8mg (26.7%, be about 6000 by the MALDI determining molecular weight).

Embodiment 2

The mPEG-5K-SPA-PheB1-insulin bonder of single PEG-ization

N ^{α B1}Synthesizing of-methoxy poly (ethylene glycol) 5K-insulin (mPEG5K-PheB1-insulin)

Two-N of the new purification that 150mg (about 0.025mmol) obtains from embodiment 1 ^{α A1}, N ^{ε B29}-t-Boc-insulin is dissolved among the 4mL DMSO that contains 95 μ L triethylamines.In insulin solutions, add 169mg (0.032mmol) mPEG-SPA-5000 (m-PEG-succinyl phosphorons amino propyl acid, mPEG-O-CH ₂CH ₂C (O) O-butanimide, molecular weight 5000).After room temperature incubated overnight (29 hours), the mPEG-insulin derivates that obtains is diluted to 100mL with deionized water, to deionized water dialysis 4 hours, lyophilization then.Cryodesiccated product is dissolved among the anhydrous TFA of 4mL again, and keeps 1.5 hours under 0 ℃ to remove the Boc blocking group in nitrogen.De-protected mPEG-insulin is diluted to 50mL with deionized water, to 0.1% NH ₄HCO ₃With the deionized water dialysed overnight.The product lyophilization is obtained white powder.Output is 117.6mg (41.6%, be about 11311.6 by the MALDI determining molecular weight).

Based on mass spectrometric data, single bonded content of insulin is about 90%, has confirmed the site-specific character of this synthetic method.Other characteristic provides in embodiment 5.The insulin content of the product that obtains is 51.3%.For ease of quoting N ^{α B1}-methoxy poly (ethylene glycol) 5K-propionamido--insulin or mPEG5K-PheB1-insulin will be called as " 5KPEG insulin " in this article.

Embodiment 3

Synthesizing of mPEG-2K-SPA-insulin bonder

Following method is used for the insulin of preparation with non-locus specificity (promptly at random) mode PEGization, and having used molecular weight is the linear polyethylene glycol of about 2,000 daltonian examples.0.1012g (molecular weight 5826 dalton 0.01737mmol) are dissolved in the anhydrous DMSO of 0.5mL to insulin, use 50 μ L triethylamines (0.3587mmol, 20 times of excessive mole numbers) to handle then.In above-mentioned reactant mixture, add 52mg m-SPA-2000 (molecular weight is about 2000 dalton for mPEG-succinyl phosphorons amino propyl acid, Shearwater company, 0.02605mmol, 1.5 times of excessive mole numbers).Mixture stirred under room temperature and nitrogen about 17 hours.Then reactant mixture is dissolved among 0.1% the TFA, makes cumulative volume reach 5.5mL, then by the reversed-phase HPLC purification, use the C-18 post, acetonitrile/0.1%TFA is an eluent.Reversed-phase HPLC has shown the mixture of products that contains single-(combining a PEG) and two-PEGization (combining two PEG), and this compositions is referred to herein as " 2K peg insulin ".

Output: 68mg

Insulin content by the RP-HPLC analysis: 50.5mg

Embodiment 4

Synthesizing of mPEG-750Da-SPA-insulin bonder

Prepare main by the compositions of forming at the insulin of B1 site PEGization in site-specific mode, use a kind of representative poly ethyldiol modified dose, the 750 daltonian Polyethylene Glycol that promptly have the linearity that is suitable for being covalently bound to succinyl phosphorons amino propyl acid end on the insulin.

4A, two-N ^A1, N ^B29Synthesizing of-t-Boc-insulin

The insulin of two protections is prepared as follows.602mg insulin human (0.103mmol) is dissolved in the 3.0mL anhydrous dimethyl sulfoxide (DMSO) that contains 166 μ L triethylamines.In insulin solutions, add 50 μ L, two-tert-butyl group-bicarbonate (0.215mmol).Room temperature was placed after 60 minutes, and reactant liquor is poured in the 240mL acetone, and the HCl that adds 3 6M then is with initial flocculation.Precipitation is by isolated by filtration, and is dry in a vacuum.Product is used the preparation HPLC purification, uses Waters 25 * 100mm C18 post (particle mean size 15 μ m, aperture 100A).The mixture of the deionized water of acetonitrile and 0.1%TFA is as eluent, elution speed 3.0mL/min.Collect product, distillation is to remove acetonitrile, lyophilization then.Output is 164.8mg (26.7%, be about 6000 by the MALDI determining molecular weight).

Synthesizing of 4B, mPEG-750Da-SPA-PheB1-insulin bonder

Two-N of the new purification that (63.4mg about 0.01056mmol) obtains from embodiment 4A ^A1, N ^B29-t-Boc-insulin is dissolved among the 0.5mL DMSO that contains 200 μ L triethylamines.In insulin solutions, add 33mg (0.03137mmol, the mSPA750 molecular weight is approximately 1040 dalton) mPEG-SPA-750 (m-PEG-succinyl phosphorons amino propyl acid, mPEG-O-CH ₂CH ₂C (O) O-butanimide, PEG MW 750).After the incubated overnight under the room temperature (29 hours), add 300 μ L TFA in reactant mixture, the mPEG-insulin derivates that obtains precipitates in the 100mL ether, then vacuum drying.Output is about 28.5mg, and the insulin content of measuring by reversed-phase HPLC is 21.3mg (33.6%, the molecular weight of measuring by MALDI is about 6639.3 dalton).In order to simplify, said composition is referred to herein as " 750PEG insulin ".

This material has been carried out twice different synthesizing, all utilize aforesaid synthetic method, have only some exception: a synthetic used mPEG-SPA-750 is 7: 1 with the mole ratios of insulin, and another synthesizes used mPEG-SPA-750 and the mole ratios of insulin is 3: 1.Be referred to herein as " 750-1 peg insulin " (mole ratios of PEG reagent and insulin is 7: 1) and " 750-2 peg insulin " (mole ratios of PEG reagent and insulin is 3: 1) from these the two kinds product compositionss that prepare.

Embodiment 5

The evaluation of exemplary PEG-analgesic composition

Use various analytical technologies that the character of the insulin bonder compositions of above-mentioned PEGization is made further research.

Use mass spectrography the relative quantity single, double and three-bonded insulin (being also referred to as peg insulin monomer, dimer and trimer) that exists in every kind of compositions to be assessed according to relative peak area.The results are shown in following table 1.

The relative quantity of table 1, the single, double and three-bonded insulin that obtains according to mass spectrum

The PEG-analgesic composition	Unijunction compound %	Binode compound %	Three conjugate %
				The 5K peg insulin	91	4	Undetermined
750-1 PEG insulin	46	39	15
				750-2 PEG insulin	60	32	8
The 2K peg insulin	51	45	Undetermined

Above-mentioned 750-1,750-2 and 2K PEG-analgesic composition are carried out aperture exclusion chromatography (SEC), in Waters 2690 HPLC systems, use the ShodexSEC post (part number KW-802.5) of two assembled in series.Mobile phase is made up of the water of 22% glacial acetic acid and 33% acetonitrile (v/v).Chromatographic data is used as the another kind of method of determining the relative quantity of every kind of single, double and three-bonded insulin that contains in these compositionss.The results are shown in following table 2.Data in his-and-hers watches 1 and the table 2 compare as can be seen, and the result of intimate unanimity is provided aspect the relative quantity of every type of conjugate that these two kinds of diverse ways exist in compositions.

The relative quantity of table 2, the single, double and three-bonded insulin that obtains according to HP-SEC

The insulin type	Unijunction compound %	Binode compound %	Three conjugate %	Other material %
					PEG 750-1	48	47	5	0
PEG 750-2	66	26	7	2
					PEG 2000	40	51	Do not detect	9

The distribution of diverse location conjugate in every kind of this three kinds of exemplified composition is determined in the research of having carried out other, i.e. the degree that replaces of three possible binding site A-1 Gly, B-1 PheH or each position among the B-29 Lys.(DTT Sigma) is used to reduce disulfide bond in the insulin sample to dithiothreitol, DTT, causes the covalent bond between INSULIN A chain and the B chain to be broken.

For carrying out reduction reaction, PEG-insulin sample is dissolved in the 8M carbamide that contains the 0.4M ammonium bicarbonate, make insulin quality suitable in every kind of conjugate species reach about 0.2mg/mL.Be dissolved in the water DTT (7mg/mL) formation DTT aqueous solution.Add 1 part of DTT solution then in every kind of insulin solutions of 5 parts, reduction reaction was carried out 15 minutes at 50 ℃.Use iodoacetamide (Sigma) with reductive 750 peg insulin compositions alkylations.Before chromatography and enzymolysis, 6 parts of PEG-insulin solutions and 1 part of 100mM iodoacetamide are reacted.Use HPLC analytical reactions product then.According to the amount of INSULIN A chain that after control sample, elutes or B chain (owing to Polyethylene Glycol in conjunction with) estimate the percent with INSULIN A chain or B chain combination.Therefore for contrast, the peak that elutes after these can not occur in the retention time of expection.Relative peak area is used to provide indication to the percent of Polyethylene Glycol and INSULIN A chain or B chain combination.

For further research PEG is attached to relative quantity on B-29 LyS and the B-1 Phe, the reduction that obtains from above-mentioned DTT reduction reaction and the A chain of alkylating 750-1 and 750-2 peg insulin compositions and B chain be used further the order-checking level enzyme---endo protease Glu-C (Sigma) digests.Preparation contains the ammonium bicarbonate aqueous solution of 0.125 μ g/ μ L enzyme.Before adding enzyme liquid, the insulin concentration of every kind of reduction reaction mixture in containing the 8M carbamide of 0.4M ammonium bicarbonate is 0.05 μ g/ μ L.In 40 parts of insulin solutions, add 1 part of enzyme liquid then.Produce the insulin peptide section of A1-A4, A5-A17, A18-A21, B1-B13, B14-B21 and B22-B30 with endo protease Glu-C digestion back.

The fragment that the A chain of enzymatic digest 750-1 and 750-2 peg insulin compositions and B chain obtain is analyzed to assess the population distribution that PEG in every kind of these compositions is attached to the site on the insulin with HPLC.Do not have the percent at the peak of appearance to provide a kind of assessment for the segmental amount that is attached on the PEG with respect to contrast, this is because that fragment other places on tomographic map are eluted.

The distribution of PEG binding site in table 3A, the exemplary PEG-insulin preparation

The insulin type	The bonded percent in A-1 site	The bonded percent in B-1 site	The bonded percent in B-29 site
				PEG 750-1	30	95	21
PEG 750-2	11	95	15
				PEG 2000	63	85 *

^*The data of just reducing recovery and not having to digest

The numeral of table 3A is based on each site by the bonded probability of a hundred per cent.For example, each unijunction compound kind have three kinds of possible configurations (list-A1, list-B1 and single-B-29), each binode compound also have three kinds of configurations (two-A1, B-1, two-A1, B-29 and two-B1, B29).Check the data among the table 3A, for example, for PEG-750-1, in all possible species that exist in compositions, 95% PEG-insulin bonder has a Polyethylene Glycol that covalently bind on the B-1 site.

Table 3B, various possible conjugate species

Type	List-conjugate			Two-conjugate			Three conjugates	HMWP
									Species #	1	2	3	4	5	6	7	8
Binding site	A-1	B-1	B-29	A- 1+B-1	A-1+B- 29	B-1+B- 29	A-1+B- 1+B-29	Bonded insulin dimer

Embodiment 6

The comparison of enzymatic digest 750-2 peg insulin and unmodified insulin speed

750-2 peg insulin and insulin are compared by the speed of chymase enzymatic digest.

The phosphate buffer of the pH7.8 of preparation 1mg/mL insulin contrast and PEG 750 insulins-2 compositions.The 1mM hydrochloric acid solution of preparation 1mg/mL chymase.In 20 parts of insulin solutions, add 1 part of enzyme liquid.Approximately each hour taken out duplicate samples such as a small amount of from mixed liquor.

Developed a kind of RP (anti-phase)-HPLC method, used the C-18 post, mobile phase contains sodium perchlorate, phosphoric acid and acetonitrile.Use acetonitrile gradient to come the insulin species of classification eluting PEGization, detect at the 214nm place and obtain one group of distinguishable slightly peak.This group peak is a peak and is labeled as peg insulin by manual integration.In the process of digestion, with the minimizing mapping (Fig. 1) of complete peg insulin and insulin.Their half-life when having chymase are estimated.

The required time of main component of the 750-2 peg insulin compositions of enzymatic digest one half strength is 5 double-lengths of the insulin required time of unmodified.That is to say, compare, will spend the time of 5 double-lengths with the insulin of the illustrated PEGization of pancreas milk reducing protease digesting one half strength with the insulin of routine.These results show, compare with unmodified insulin, owing to strengthened proteolysed resistance, the peg insulin conjugate has the potentiality that prolong residence time in alveolar.

Embodiment 7

The assessment (P-2001-015) of serum glucose and insulin concentration behind the administration 5K peg insulin in the rat medium-sized vein

Implement this research and be in order to determine that insulin in the 5K peg insulin compositions is after carrying out chemical modification through the 5K polyglycol chain with example, whether its activity is also kept, simultaneously in order to explore dosage and the glucose response curve of these compositionss when the intravenous administration.

Expose nape, subcutaneous pre-(being positioned at neck/femur vein [JVC/FVC]) male Sprague Dawley rat that plugs in conduit that the screw thread access port arranged by Hilltop Lab Animal Inc. provide (P.O.Box 183, Scottdale, PA15683).The jugular vein intubate is filled to keep open with the solution (tube chamber implant) of polyvinylpyrrolidone (PVP-molecular weight 40000), normal saline and the heparin sodium of pharmaceutical grade.Studying the same day, take out the nylon fiber plug of sealing intubate, replace with the blunt conduit 23Gx1 of Monoject (VWR #53498-484).Pilot system comprises that the male rat of 1 picked at random is used for placebo group, and the male rat of 2 picked at random is used for the group of non-PEGization, and the male rat of 4 picked at random is used for PEG-insulin group.Be used for the 5K peg insulin of the PEGization insulin of this research from embodiment 2.Dosage passes through intravenous administration.

Quantity/sex of animal

First day: for placebo group 1, every group of 1 male rat

For group 2, every group of 2 male rats; For group 3-5, every group of 4 male rats

Before beginning one's study, animal was by fasting 12-18 hour.Insulin human (Diosynth) is stored in-20 ℃ before use.5K peg insulin (embodiment 2) is stored in-20 ℃ before use.Prepare two kinds of different solution that are used for administration:

The solution that is used for intravenous administration

The insulin human of non-PEGization (1.0mg/mL liquid storage): in 1.0mL PBS, add the 1.0mg insulin powder.

5K peg insulin (1.0mg/mL insulin human, concentration is based on insulin rather than conjugate): in 6.0mL PBS, add 11.7mg 5K peg insulin powder.

By sucking isoflurane (isoflurane) anesthetized animal.Give intravenous dosages (every animal 300 μ L) by FVC, then with the cross-contamination of duct ligation with elimination and extraction blood.All blood samples extract by JVC.Phosphate buffer (PBS) arrives group 1 with the dosage intravenous administration of 300 μ L.The insulin human of non-PEGization arrives group 2 with the dosage intravenous administration of every animal 20 μ g.The insulin human of PEGization with the dosage intravenous administration of every animal 20 μ g to group 3, with the dosage intravenous administration of every animal 40 μ g to group 4, and with the dosage intravenous administration of every animal 30 μ g to group 5.Before administration, collected blood sample (about 500 μ L) from JVC in 10,15,30,60,120 and 180 minutes after (preceding 2 to 2.5 hours of administration), the administration.Small amounts of blood is placed on the glucose reagent paper, and (Bayer Corp., Elkart IN) measure blood glucose by Glucometer Elite glucose detection instrument.Remaining sample is put into serum separator tube, place the centrifuge separating blood.Serum is poured in another test tube then, (RIA) analyzes by radioimmunoassay method.Use Microsoft  Excel 2000 calculating mean values and standard deviation (SD).

Experiment summary in table 4, the body

Be actual dosage and every group of actual number of animals of using below.Research was finished in one day.

Group number	Compositions	The administration route	The daily dose of total insulin (μ g/ animal)	Number of animals/sex
					1	Placebo	Intravenous	0	1 male
2	Non-peg insulin	Intravenous	20	2 male
					3	Peg insulin	Intravenous	20	4 male
4	Peg insulin	Intravenous	40	4 male
					5	Peg insulin	Intravenous	30	4 male

The result shows 5K peg insulin compositions biologically active, and promptly insulin molecule has been through having kept activity after polyethyleneglycol modified, and this from the ability of its blood sugar lowering as can be seen.Behind the insulin of intravenous administration PEGization, the average insulin concentration in the serum is dose-dependent, has also observed the reduction of the glucose level of dose dependent simultaneously.The results are summarized among Fig. 2 and Fig. 3.Fig. 2 be the illustrated PEGization of intravenous administration with the compositions of the insulin of non-PEGization after average insulin concentration map in the serum; Fig. 3 is the blood sugar concentration figure after the above-mentioned compositions of intravenous administration.

Embodiment 8

The pulmonary administration of 5K peg insulin (P-2001-017)

By administration in the trachea, with a kind of PEGization of example insulin---the 5K peg insulin is administered to rat, whether also keep with definite (1) its activity after being administered into pulmonary, and (2) if any, it is to the influence of serum insulin and blood sugar concentration when directly being administered into pulmonary.

Storage liquid

The insulin of non-PEGization: 1mL PBS is added in the 1.0mg insulin powder with preparation 1mg/mL storage liquid.The storage liquid of insulin (contrast) is in preparation on the same day of research beginning.

5K peg insulin: 4.0mL PBS is added in the 7.8mg 5K peg insulin powder to prepare the storage liquid of 1mg/mL (based on insulin).

Use drug solns

Every animal 40 μ g insulins: in medication 2 hours, 667 μ g insulin storage liquid are added among the 4.33mL PBS.

Every animal 150 μ g insulin Bs-1: in medication 2 hours, 2.5mL 5K peg insulin storage liquid is added among the 2.5mL PBS.

Intratracheal instillation

In a plexiglas anesthetic room, make rat suck with about 5 minutes of the 3.0-5.0% isoflurane (Abbott Laboratories) of oxygen mix so that rat is slightly anaesthetized.With filling food pin (the Popper ﹠amp that is installed on the 1mL syringe; Sons Inc.; 18x3 " W2-1/4mm ball, NewHyde Park, NY 11040) insert in the mouth of rat, to be issued to just be positioned at the prominent top of main joist trachea to finish administration.In the time will irritating food pin insertion trachea, use the ball of irritating the food pin to determine by the degree of roughness of the cartilaginous ring under the sensation throat skin whether insertion is suitable.Utilize this method with dosed administration in lung, extract then and irritate the food pin.

In this research, used 14 (7 every group) inside to have the male rat (Hilltop Lab Animal, Scottsdale, PA (300-350g)) of the fasting of jugular vein conduit (JVC).Be administered into group 1 in the dosage trachea of the insulin human of non-PEGization with 40 μ g/300 μ L.Be administered into group 2 in the dosage trachea of the human insulin preparation of PEGization with 150 μ g/300 μ L.15,30,60,120,240,360,480 and 720 minutes collection blood samples (about 500 μ L) after (preceding 2 to 0.25 hours of administration), the administration before administration.Small amounts of blood is placed on the glucose reagent paper, and (Bayer Corp., Elkart IN) measure blood glucose by Glucometer Elite glucose detection instrument.Remaining sample is put into serum separator tube, analyze by radioimmunoassay method.Use Microsoft  Excel 2000 calculating mean values and standard deviation (SD).Because conduit stops up, animal 2 and 3 gives up from research.

Experimental summary in table 5, the rat body

Be actual dosage and every group of actual number of animals of using below.

Group number	The insulin type	Route of administration	Number of animals/sex	Total insulin daily dose (μ g/ animal)	The medication natural law
						1	Insulin	In the trachea	7 male	40	1
2	The 5K peg insulin	In the trachea	7 male	150	1

Dosage level in table 6, the body

Group number	The insulin type	Total insulin daily dose (μ g/ animal)	Dose volume (μ L)	Medication solution concentration (μ g/mL)
					1	Insulin	40	300	133.33
2	The 5K peg insulin	150	300	500

Mean concentration in serum and blood is mapped to insulin after the administration in the trachea and 5K peg insulin, is presented at respectively among Fig. 4 and Fig. 5.The result shows that the analgesic composition of PEGization of the present invention has activity when transmitting pulmonary and staying in the lung.Pharmacokinetic data proves that further the insulin of PEGization has not only entered blood circulation by lung, and has kept activity simultaneously, as can detected insulin level corresponding to non-endogenous insulin in serum indicated.Judge that according to the insulin level in the observed blood in after the administration in trachea about 1 hour as if the insulin of PEGization does not stop basically in lung, after administration, just pass pulmonary in very short time and enter blood flow.The result also shows, the insulin of PEGization, and when when the pulmonary administration, effective blood sugar lowering.Yet in the present embodiment, the insulin of PEGization is compared with the insulin of non-PEGization, at the dosage of institute's administration in that to seem effectiveness aspect the blood sugar lowering lower.The islets of langerhans of the pharmacokinetics of the insulin of administration PEGization and pharmacodynamics response curve and non-PEGization have similarity to a certain degree in the trachea, although according to the curve of Fig. 4, it is longer than the insulin of non-PEGization to seem the action time of PEG-insulin.Based on the guideline that provides at this, and the medication demand of the insulin product of modifying according to particular chemical, target patient's population, the disease that will treat etc., those skilled in the art can easily finish dosage and polyethyleneglycol modified dose concrete further optimization.

Embodiment 9

The pulmonary administration of 750-1 peg insulin (P-2001-025)

By administration in the trachea, with a kind of representational PEGization insulin---the 750-1-PEG insulin administration is to rat.Carry out this study portion and be for study covalent bond one or more molecular weight be approximately the effect of analgesic composition when it is sent to pulmonary of 1000 dalton or following polyglycol chain.

Research is carried out as described in the front embodiment 8 basically in the body of rat.Summarize in accurate therapeutic regimen and the dosage table below thereafter.

Table 7

Group number	The insulin type	Route of administration	Size of animal/sex	Total insulin daily dose (μ g/ animal)	The medication natural law
						1	Insulin	In the trachea	2 male	80	1
2	750-1 PEG insulin	In the trachea	4 male	100	1
						3	750-1 PEG insulin	In the trachea	4 male	300	1
4	750-1 PEG insulin	In the trachea	4 male	500	1

Table 8

Group number	The insulin type	Total insulin daily dose (μ g/ animal)	Dose volume (uL)	Medication solution concentration (μ g/mL)
					1	Insulin	80	300	266.67
2	The 750-1 peg insulin	100	300	333.33
					3	The 750-1 peg insulin	300	300	1000.00
4	The 750-1 peg insulin	500	300	1666.67

To insulin and 750-1 peg insulin in rat in the trachea serum insulin after the administration and blood sugar concentration map, be presented at respectively among Fig. 6 and Fig. 7.Average serum insulin concentration figure from Fig. 6 can see, the insulin of natural or non-PEGization reached the highest serum-concentration in the time of about 15 minutes, and the analgesic composition of PEGization reaches the highest serum-concentration at about 6 hours (every animal 100 μ g) and 8 hours (every animal 300 μ g), has proved the long-acting character of these compositionss when arriving pulmonary by inhalation.As can be seen from Figure 6, the insulin of unmodified was got back to baseline in about 6 hours after administration, and the insulin level of the insulin of PEGization in the time of 6 hours still be significantly higher than baseline (be higher than baseline value about 3 to 7 times or higher).In addition, the insulin of administration PEGization makes the insulin level of whole body even still kept in 12 hours after administration and do not get back to baseline in the trachea.In fact, the insulin level of PEGization insulin is more than 3 times of baseline value (value of unmodified insulin) when 8 hours and 12 hours.These results' figure shows in Fig. 6.

Generally speaking, when pulmonary administration, the 750-1 peg insulin is compared with the insulin of unmodified and has been produced higher general insulin level.In addition, even the general insulin level of the insulin group of PEGization still was significantly higher than baseline in the time of 12 hours.That is to say that at least 2 double-lengths of holding time of the insulin level that the insulin group of PEGization raises are in unmodified insulin.These data prove that further the insulin of PEGization passes after the pulmonary still biologically active, and compare with unmodified insulin the whole body of time lengthening insulin level is provided.

Fig. 7 provides average blood sugar concentration map behind the insulin of administration non-PEGization and 750-1 PEGization in the trachea.For PEGization insulin group, blood glucose response level and serum insulin levels relatedness are fine.(that is to say, when serum insulin levels raises, also observe the inhibition/reduction of corresponding blood glucose simultaneously.) as can be seen from Figure 7, PEGization insulin compounds of the present invention is when oral when being administered into pulmonary, compare with natural insulin and show onset fast, rather than the onset of the delay of performance usually of many slow releasing preparation.That is to say, to the very fast generation after the administration that is suppressed at of glucose.In addition, the insulin of natural or non-PEGization reached maximum glucose in about 2 hours reduces, and the insulin of PEGization after using 500 μ g, 100 μ g and 300 μ g dosage, reach the time of maximum glucose reduction extend at least 4 hours respectively, 6 hours and 8 hours.So the PEGization insulin is when pulmonary administration, the insulin that reaches the non-PEGization of time ratio of maximum glucose reduction has prolonged 2 to 4 times.Generally speaking, the 750-1 peg insulin is compared with unmodified insulin, and its glucose suppresses to have increased significantly the time above 12 hours.In the time of 8 hours, it is normal that the glucose level of unmodified insulin group has recovered basically, and the glucose level of peg insulin group is lower 1.3 to 3 times than unmodified insulin group.The glucose level of the insulin group of PEGization even do not return to baseline in the time of 12 hours yet, this glucose that shows that further chemically derived analgesic composition of the present invention has a prolongation suppresses ability.

Embodiment 10

The pulmonary administration of 750-1 peg insulin (P-2002-001)

In the research similar, by administering mode in the trachea 750-1 peg insulin is administered to rat than the low dosage of dosage that uses among the embodiment 9 to the foregoing description 9.

The research of the interior rat of trachea is carried out as described in the front embodiment 8 basically in the body.Summarize in accurate therapeutic regimen and the dosage table below.

Table 9

Group number	The insulin type	Route of administration	Size of animal/sex	Total insulin daily dose (μ g/ animal)	The administration natural law
						1	Insulin	In the trachea	5 male	80	1
2	750-1 PEG insulin	In the trachea	5 male	80	1
						3	750-1 PEG insulin	In the trachea	5 male	160	1

Table 10

Group number	The insulin type	Total insulin daily dose (μ g/ animal)	Dose volume (μ L)	Medication solution concentration (μ g/mL)
					1	Insulin	80	300	266.7
2	750PEG insulin-1	80	300	266.7
					3	750PEG insulin-1	160	300	533.3

To unmodified insulin and 750-1 peg insulin in rat in the trachea serum insulin after the administration and blood sugar concentration map, the result is presented at respectively among Fig. 8 and Fig. 9.Average serum insulin concentration figure from Fig. 8 can see, the insulin of natural or non-PEGization reached the highest serum-concentration in the time of about 15 minutes, and the analgesic composition of PEGization reaches the highest serum-concentration at 2 hours (every animal 80 μ g) and 6 hours (every animal 160 μ g).That is to say that when by pulmonary administration in systemic circulation the time, the natural or non-PEGization insulin of time ratio that the insulin that PEG modifies reaches maximum serum insulin concentration has prolonged 8 to 24 hours.As can be seen from Figure 8, the insulin of unmodified was got back to baseline in about 12 hours after administration, and the insulin group of PEGization is 2.5 to 3.5 times of baseline value at same 12 hours its insulin levels of time point.The insulin level of PEGization insulin group was just got back to baseline up to about 25 hours, this means with the unmodified insulin group and compare that PEGization insulin group is got back to the time that baseline will be spent two double-lengths.For PEG flower insulin group, the time that the insulin level of whole body is kept is approximately the twice (25 hours to 12 hours) of unmodified insulin group.Reaching about 6 hours time points, the insulin level of two PEGization insulin groups corresponding substantially with the dosage of administration (that is to say that the insulin concentration of the group of every animal 160 μ g is approximately the twice of the group of every animal 80 μ g).

Fig. 9 provides average blood sugar concentration map behind the insulin of administration non-PEGization and 750-1 PEGization in the trachea.25 hours the time, the glucose of two PEGization insulin groups suppresses still not get back to baseline after administration, and this is opposite with the unmodified insulin group.Similar to the result of embodiment 9, the persistent period that the general status proof glucose of PEGization insulin group suppresses extended to more than 25 hours.In the time of 8 hours, the glucose level of unmodified insulin group is normal near recovery, and the glucose level of peg insulin group is lower about 1.5 times than unmodified insulin group.These results show that further the insulin of the modification with one or more polyalkylene glycol moieties has produced the good bioavaliability that passes pulmonary, and general insulin level that prolongs and glucose inhibition.

Embodiment 11

Pulmonary administration 750-2 peg insulin (P-2002-003)

By administration in the trachea, with a kind of analgesic composition of representational PEGization---the 750-2-PEG insulin administration is to rat.Carry out this research and be for the insulin of the PEGization of further exploring various dose and the non-PEGization effect when the direct pulmonary administration.The insulin of PEGization and non-PEGization form is with the dosed administration animal of every animal 80 μ g insulins.The research of rat is carried out as described in the front embodiment 8 basically in the body.Summarize in accurate therapeutic regimen and the dosage table below thereafter.

Table 11

Group number	The insulin type	Route of administration	Size of animal/sex	Total insulin daily dose (μ g/ animal)	The medication natural law
						1	Insulin	In the trachea	7 male	80	1
2	750 PEG-2 insulins	In the trachea	7 male	80	1

Table 12

Group number	The insulin type	Total insulin daily dose (μ g/ animal)	Administration volume (uL)	Medication solution concentration (μ g/mL)
					1	Insulin	80	300	266.7
2	750 PEG-2 insulins	80	300	266.7

Figure 10 has shown average serum insulin concentration figure after non-PEGization insulin and 750-2 peg insulin are with the dosage intratracheal instillation of every animal 80 μ g.Figure 11 has shown average blood sugar concentration figure after non-PEGization insulin and 750-2 peg insulin are with the dosage intratracheal instillation of every animal 80 μ g.The result is similar to the result of acquisition among the embodiment 9 and 10.

The pharmacokinetic parameter tabulation of embodiment 10 and 11 is provided below.Bioavaliability is absolute bioavaliability (promptly comparing with the intravenous administration insulin).

Table 13, average serum insulin pharmacokinetics

Embodiment	The insulin type	Approach	Dosage μ g/ animal	C max μU/mL	T maxMinute	AUC μU*min/mL	Absolute bioavaliability
								9(P-2001- 25)	Insulin	In the trachea	80	56	15	12878
9	750-1 PEG	In the trachea	100	64	368	27954
								9	750-1 PEG	In the trachea	300	160	188	50691
9	750-1 PEG	In the trachea	500	3474	184	255881
								10(P-2002- 001)	Insulin	In the trachea	80	132	15	28167
10	750-1 PEG	In the trachea	80	56	210	36818
								10	750-1 PEG	In the trachea	160	117	78	60713
Intravenous reference (P-2002-002)	Insulin	Intravenous	20	3057	5	44388
								The intravenous reference	750-2 PEG	Intravenous	20	2638	7	63190
The intravenous reference	750-2 PEG	Intravenous	30	3510	5	62746
								11(P-2002- 003)	Insulin	In the trachea	80	89	24	22203	12.5
11	750-2 PEG	In the trachea	80	164	73	57639	32 ** 32 ***

^*Exceptional value is not removed from data set.

^*Dosage with respect to every animal of intravenous 20 μ g.The value of removing after the exceptional value is 22%

^{* *}Dosage with respect to every animal of intravenous 30 μ g.The value of removing after the exceptional value does not change

Absolute bioavaliability is calculated as follows:

Embodiment 12

Pulmonary administration 2K peg insulin (P-2002-010)

By administration in the trachea, with the exemplary PEGization analgesic composition of another kind---the 2KPEG insulin administration is to rat.The preparation that is used for the 2K peg insulin of this research is described at embodiment 3.Non-PEGization insulin is with the dosed administration animal of every animal 80 μ g insulins.The 2K peg insulin is with the dosed administration animal of every animal 300 μ g, 600 μ g, 900 μ g, 1200 μ g insulins.The research of rat is carried out as described in the front embodiment 8 basically in the body.Summarize in accurate therapeutic regimen and the dosage table below thereafter.

Table 14

Group number	The insulin type	Route of administration	Size of animal/sex	Total insulin daily dose (μ g/ animal)	The medication natural law
						1	Insulin	In the trachea	3	80	1
2	PEG 2K-1 insulin	In the trachea	3	600	1
						3	PEG 2K-1 insulin	In the trachea	3	80	1
4	PEG 2K-1 insulin	In the trachea	3	160	1
						5	PEG 2K-1 insulin	In the trachea	3	300	1
6	PEG 2K-1 insulin	In the trachea	3	900	1
						7	PEG 2K-1 insulin	In the trachea	3	1200	1

Table 15

Group number	The insulin type	Total insulin daily dose (μ g/ animal)	Dose volume (uL)	Medication solution concentration (mg/mL)
					1	Insulin	80	300	0.267
2	PEG 2K-1 insulin	600	300	2.0
					3	PEG 2K-1 insulin	80	300	0.267
4	PEG 2K-1 insulin	160	300	0.533
					5	PEG 2K-1 insulin	300	300	1.0
6	PEG 2K-1 insulin	900	300	3.0
					7	PEG 2K-1 insulin	1200	300	4.0

Figure 12 has shown in the trachea average blood sugar concentration figure after the administration.The PEGization analgesic composition is observed good dose response (higher 2K peg insulin dosage causes blood sugar concentration to reduce manyly) when pulmonary administration.Although for the compositions of PEGization and non-PEGization, the time point that reaches maximum glucose inhibition in the curve all was shown as about 3 hours, and there were significant differences aspect the persistent period that glucose suppresses for the figure of PEGization and non-PEGization insulin.Specifically, for about 6 hours later time points, locate at three higher 2K PEGization insulin doses (every animal 600 μ g, 900 μ g and 1200 μ g), glucose level is suppressed, and significantly is lower than non-PEGization insulin.These results further prove, can reach the general effect of prolongation by the insulin of pulmonary administration PEGization.

Embodiment 13

The assessment (P-2002-009) of serum glucose and insulin concentration behind the interior administration 2K peg insulin of rat medium-sized vein

Carry out this research and be in order further to explore the activity of insulin in an example 2K peg insulin compositions, and in order to determine blood glucose effectively can be reduced to about 30 intravenous (i.v.) using dosages to the PEGization insulin human (PEG 2K-1) of 40mg/dL concentration.

Use generalized compositions, animal groups and dosage in the following table, according to embodiment 7 in the similar step described experimentize.

Table 16

Group number	The insulin type	Route of administration	Size of animal/sex	Total insulin daily dose (μ g/ animal)	The medication natural law
						1	Insulin	Intravenous	2 male	20	1
2	PEG 2K-1 insulin	Intravenous	2 male	20	1
						3	PEG 2K-1 insulin	Intravenous	2 male	30	1
4	PEG 2K-1 insulin	Intravenous	2 male	40	1
						5	PEG 2K-1 insulin	Intravenous	2 male	80	1
6	PEG 2K-1 insulin	Intravenous	2 male	160	1

Table 15

Group number	Contrast/test event	Total insulin daily dose (μ g/ animal)	Dose volume (μ L)	Medication solution concentration (μ g/mL)
					1	Insulin	20	300	67
2	PEG 2K-1 insulin	20	300	67
					3	PEG 2K-1 insulin	30	300	100
4	PEG 2K-1 insulin	40	300	133
					5	PEG 2K-1 insulin	80	300	267
6	PEG 2K-1 insulin	160	300	533

Figure 13 shown with every animal 20 μ g (non-PEGization insulin) and every animal 20,30 and 40 μ g (2K peg insulin) dosage with the insulin of non-PEGization and 2K peg insulin intravenous administration after average serum insulin concentration figure.Figure 14 shown with above-mentioned dosage with the insulin of non-PEGization and 2K peg insulin intravenous administration after average blood sugar concentration figure.

Claims (77)

1. analgesic composition that is used for pulmonary administration, described compositions contains the formed conjugate of molecule covalent bond of the hydrophilic polymer of insulin and the existence of one or more non-natural, wherein said compositions is with (i) atomized liquid form, and perhaps (ii) dried forms exists.

2. the described analgesic composition of claim 1, wherein said conjugate does not contain lipophilic portion.

3. the analgesic composition in the claim 1, the hydrophilic polymer that wherein said non-natural exists is a poly alkylene glycol.

4. the analgesic composition in the claim 1, the hydrophilic polymer that wherein said non-natural exists is a Polyethylene Glycol.

5. the analgesic composition in the claim 2, the hydrophilic polymer that wherein said non-natural exists is a Polyethylene Glycol.

6. the described compositions of claim 4 is characterized by absolute pulmonary bioavaliability and is higher than natural insulin.

7. the described compositions of claim 6 is characterized by the twice at least that absolute pulmonary bioavaliability is a natural insulin.

8. the described compositions of claim 4 is characterized by absolute pulmonary bioavaliability greater than 15%.

9. the described compositions of claim 8 is characterized by absolute pulmonary bioavaliability greater than 30%.

10. the described compositions of claim 4 when being administered into pulmonary, is characterized by Tmax and is at least 3 times of natural insulin.

11. the described compositions of claim 10 when being administered into pulmonary, is characterized by Tmax and is at least 5 times of natural insulin.

12. the described compositions of claim 4, wherein said Polyethylene Glycol is an endcapped.

13. the described compositions of claim 12, wherein said Polyethylene Glycol is by an alkoxy grp endcapped.

14. the described compositions of claim 4, wherein said Polyethylene Glycol are selected from linear polyethylene glycol, branch's Polyethylene Glycol, bifurcated Polyethylene Glycol and dumbbell shaped Polyethylene Glycol.

15. the described compositions of claim 14, wherein said Polyethylene Glycol contain a biodegradable key.

16. the described compositions of claim 14, wherein said Polyethylene Glycol contains (OCH ₂CH ₂) quantity of subunit is selected from from about 2 to 300 subunits, from about 4 to 200 subunits and from about 10 to 100 subunits.

17. the nominal mean molecule quantity that the described compositions of claim 14, wherein said Polyethylene Glycol have is to about 10,000 dalton from about 200.

18. the described compositions of claim 14, wherein said Polyethylene Glycol is linear.

19. the nominal mean molecule quantity that the described compositions of claim 17, wherein said Polyethylene Glycol have is to about 5,000 dalton from about 200.

20. the nominal mean molecule quantity that the described compositions of claim 17, wherein said Polyethylene Glycol have is to about 2,000 dalton from about 200.

21. the nominal mean molecule quantity that the described compositions of claim 17, wherein said Polyethylene Glycol have is to about 1,000 dalton from about 200.

22. the described compositions of claim 4, wherein said insulin is a natural insulin.

23. the described compositions of claim 4, the purity of wherein said conjugate is greater than 90%.

24. the described compositions of claim 4, wherein said insulin on its one or more amino sites with the Polyethylene Glycol covalent bond.

25. the described compositions of claim 24, wherein about at least 75% B-1Phe site and Polyethylene Glycol covalent bond on the insulin.

26. the described compositions of claim 25, wherein about at least 90% B-1Phe site and Polyethylene Glycol covalent bond on the insulin.

27. the described compositions of claim 24, it contains the mixture of monomer and dimer insulin bonder.

28. the described compositions of claim 27, it also contains the trimer insulin bonder.

29. the described compositions of claim 4, coupling part and the described Polyethylene Glycol covalent bond of wherein said insulin by being positioned at Polyethylene Glycol one end.

30. the described compositions of claim 4, wherein said Polyethylene Glycol be with before insulin combines, and has at the one end to be fit to and the covalently bound activatory coupling part of insulin.

31. the described compositions of claim 30, wherein said activatory coupling part are fit to combine with reactive insulin amino group.

32. the described compositions of claim 31, the reactive functional groups that wherein said activatory coupling part is contained is selected from N-hydroxy-succinamide active ester, activated carbon acid esters, aldehyde and acetal.

33. the described compositions of claim 29, wherein insulin is by an amido link and Polyethylene Glycol covalent bond.

34. the described compositions of claim 4 exists with the atomization drying form.

35. the described compositions of claim 4 exists with dried forms.

36. the described compositions of claim 4 further contains pharmaceutically useful excipient.

37. the described compositions of claim 4 exists with spray-dired form.

38. the described analgesic composition of claim 4 needing to be used for the application of medicine of its mammiferous pulmonary administration in preparation.

39. one kind provides the method for the analgesic composition of non-immunogenic basically, described compositions is used to be administered into the pulmonary of the study subject that needs it, and described method comprises:

The molecule covalent bond of the hydrophilic polymer that insulin and one or more non-natural are existed to be providing the compositions that contains insulin-hydrophilic polymeric combination, and

By sucking the pulmonary that described compositions is administered into the study subject that needs it, the result of described administration is that described insulin enters into blood circulation by pulmonary.

40. the described method of claim 39, the hydrophilic polymer that wherein said non-natural exists is a poly alkylene glycol.

41. one kind is used to provide the protamine zine insulin method for compositions, described compositions is used to be administered into the pulmonary of the study subject that needs it, and described method comprises:

The molecule covalent bond of the hydrophilic polymer that insulin and one or more non-natural are existed to be providing the compositions that contains insulin-hydrophilic polymeric combination,

By sucking the pulmonary that described compositions is administered into the study subject that needs it, the result of described administration is that (1) described insulin enters into blood circulation by pulmonary, and the rising of insulin level was kept after administration 8 hours at least in (2) blood.

42. the described method of claim 41, the hydrophilic polymer that wherein said non-natural exists is a poly alkylene glycol.

43. the described method of claim 42, the hydrophilic polymer that wherein said non-natural exists is a Polyethylene Glycol.

44. the described method of claim 43, wherein the rising of insulin level was kept after administration 10 hours at least.

45. the described method of claim 43, wherein the rising of insulin level was kept after administration 12 hours at least.

46. the described method of claim 43, the result of wherein said administration also have the glucose level in the described study subject to be suppressed at least 10 hours after administration.

47. the described method of claim 46, the result of wherein said administration also have the glucose level in the described study subject to be suppressed at least 12 hours after administration.

48. the described method of claim 43, wherein said dosing step comprise with the described compositions of atomised form administration.

49. the described method of claim 43 also is included in the step of the described compositions of atomizing before the administration.

50. the described method of claim 43, wherein said integrating step comprise in site-specific mode insulin and Polyethylene Glycol covalent bond.

51. the described method of claim 43, wherein said integrating step comprise at random mode insulin and Polyethylene Glycol covalent bond.

52. the described method of claim 43, wherein said conjugate are when pulmonary administration, its feature is that also its absolute bioavaliability is higher than natural insulin.

53. the described method of claim 43, wherein said integrating step comprise the peg molecule covalent bond with insulin and one or more endcappeds.

54. the described method of claim 43, wherein said integrating step comprise that described Polyethylene Glycol is selected from the Polyethylene Glycol of linearity, branch, bifurcated and dumbbell shaped with the molecule covalent bond of insulin and one or more Polyethylene Glycol.

55. the described method of claim 43, wherein said conjugate does not contain lipophilic portion.

56. the described method of claim 43, wherein said compositions does not contain lipotropic component.

57. the described method of claim 43, wherein said integrating step comprise insulin and one or more molecule covalent bond that contains the Polyethylene Glycol of biodegradable key.

58. the described method of claim 43, (the OCH that wherein said Polyethylene Glycol contains ₂CH ₂) quantity of subunit is selected from from 2 to 300 subunits, from 4 to 200 subunits and from 10 to 100 subunits.

59. the nominal mean molecule quantity that the described method of claim 43, wherein said Polyethylene Glycol have is from 200 to 10,000 dalton.

60. the nominal mean molecule quantity that the described method of claim 43, wherein said Polyethylene Glycol have is from 200 to 5,000 dalton.

61. the nominal mean molecule quantity that the described method of claim 43, wherein said Polyethylene Glycol have is from 200 to 2,000 dalton.

62. the nominal mean molecule quantity that the described method of claim 43, wherein said Polyethylene Glycol have is from 200 to 1,000 dalton.

63. the described method of claim 43, wherein said combination comprise Polyethylene Glycol is attached on one or more reactive amino site of insulin.

64. the described method of claim 63, wherein said Polyethylene Glycol is incorporated on one or more reactive amino site of insulin by the bond that is selected from amide, urethanes and methene amido.

65. comprising, the described method of claim 63, wherein said combination will have the Polyethylene Glycol of the end reaction base that is selected from N-hydroxy-succinamide active ester, activated carbon acid esters, aldehyde and acetal and the one or more reactive amino site on the insulin is reacted.

66. the described method of claim 43, wherein described in conjunction with the compositions that produces at least 75% B-1Phe site and Polyethylene Glycol covalent bond on the insulin.

67. the described method of claim 43, wherein described in conjunction with the compositions that produces at least 90% B-1Phe site and Polyethylene Glycol covalent bond on the insulin.

68. the described method of claim 43, the wherein said mixture that contains monomer and dimer insulin bonder in conjunction with the compositions that produces.

69. the described method of claim 68, the wherein said conjugate that also contains the trimer insulin in conjunction with the compositions that produces.

70. at one end containing, the described method of claim 43, wherein said Polyethylene Glycol be fit to and the covalently bound activatory coupling part of insulin.

71. the described method of claim 70, the reactive functional groups that is selected from N-hydroxy-succinamide active ester, activated carbon acid esters, aldehyde and acetal is contained in wherein said activatory coupling part.

72. the described method of claim 70, the length of wherein said bound fraction is atom from 2 to 20.

73. the described method of claim 43, wherein said dosing step comprise by the described compositions of Diskus administration.

74. the described method of claim 43, wherein said dosing step comprise the described compositions of dose inhaler administration by metering.

75. the described method of claim 43, wherein said dosing step comprise by the described compositions of aerosol apparatus administration.

76. the described method of claim 43, wherein said compositions also comprises pharmaceutically useful excipient.

77. the described method of claim 43, wherein the described conjugate composition results of administration is, in 1 hour, the insulin level in the serum just reaches than 2 times of foundation level height at least after administration.

Images